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Summary 
  
 Exosomes are small membrane vesicles that are secreted by 
several cell types including tumour cells. They are formed intracellularly by 
an inward budding of the membrane of endosomal compartments which are 
converted to multivesicular bodies. Exosomes are then released into the 
extracellular environment after fusion of the multivesicular bodies with the 
plasma membrane. Upon internalization by other cells they may transfer 
proteins and RNA among cells. Tumour-derived exosomes can promote 
angiogenesis, cell proliferation, tumour cell invasion and immune evasion. 
These vesicles have been found in biological fluids such as malignant 
ascites and blood and can therefore be used not only to identify potential 
biomarkers of disease but also in vaccination. 
 Alterations in protein glycosylation are often associated with 
tumourigenesis; therefore glycan structures represent ideal targets for 
tumour specific diagnosis and new anti-tumour therapeutic strategies.  
 This research focused on the characterization and investigation of 
the biological role of protein N-glycosylation from ovarian tumour derived 
exosomes, with particular emphasis on the glycoprotein disintegrin and 
metalloprotease 10 (ADAM10). 
 Chapter 2 details the investigation of the role of N-glycosylation on 
ADAM10 intracellular localization, activity and sorting to exosomes. To 
accomplish this objective, individual ADAM10 N-glycosylation site mutants 
S269A, T280A, S441A, T553A were constructed using the QuickChange 
site directed mutagenesis approach. Western blot analysis of the ovarian 
carcinoma SKOV3 cells stably transfected with wild-type and N-
glycosylation mutants of ADAM10 showed that all potential glycosylation 
sites were occupied by high-mannose and/or complex oligosaccharides. 
Mutant T280A was found to accumulate in the endoplasmic reticulum as 
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the non-processed precursor of the enzyme, whilst S441A showed 
increased susceptibility to proteolysis. Study of ADAM10 in vivo activity 
towards the cell adhesion molecule L1, in HEK293 cells and mouse 
embryonic fibroblasts derived from the ADAM10 knockout mouse revealed 
that the mutation of ADAM10 N-glycosylation sites did not completely 
abolish enzyme activity. Accordingly, all mutants exhibited proteolytic 
activity towards proTNF-alpha in vitro. However, a reduction in the 
shedding levels was found, especially for T280A. On the other hand, all 
ADAM10 N-glycosylation mutants cleaved to their mature form were 
efficiently sorted into exosomes. Overall, these results showed the 
importance of N-glycosylation for ADAM10 processing, protection from 
proteolysis, and full-enzyme activity.  
 Exosomes can interact and be internalized by target cells; however, 
the mechanisms involved in this process are still poorly understood. 
Chapter 3 describes that SKOV3 cells were found to internalize SKOV3 
derived exosomes labelled with carboxyfluoresceine diacetate succinimidyl-
ester, by immunofluorescence microscopy, via an energy-dependent 
process. Partial colocalization with the endosome marker EEA1 and 
inhibition by chlorpromazine suggested the involvement of clathrin-
dependent endocytosis. On the other hand, an uptake inhibition in the 
presence of 5-ethyl-N-isopropyl amiloride, cytochalasin D and methyl-beta-
cyclodextrin suggested the involvement of additional endocytic pathways. 
Furthermore, proteins present in exosomes and at SKOV3 cell surface 
were at least partially required for internalization, as shown by the decrease 
in the uptake levels following proteinase K treatment. 
 The analysis of the glycosylation profiles of SKOV3 exosomes using 
lectins with different specificities revealed that they were enriched in 
specific mannose- and sialic acid-containing glycoproteins that were not 
present in cellular extracts and that may constitute exosome markers. The 
effect of glycosylation on exosome uptake was also assessed. Sialic acid 
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removal led to an increase in uptake efficiency whilst cell incubation with 
monosaccharides D-galactose, α-L-fucose, α-D-mannose, D-N-
acetylglucosamine and the disaccharide β-lactose reduced exosome 
uptake to a level comparable to that of the control D-glucose.  
 Chapter 4 addresses the further characterization of the N-glycan 
profile of vesicles secreted by ovarian tumour cells. A detailed structure 
analysis of the N-glycans of SKOV3 and OVM secreted vesicles, 
microsomal and plasma membrane fractions was performed by high 
performance anion exchange chromatography with pulsed amperometric 
detection (HPAEC-PAD) and matrix assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF-MS). Glycans of the di-, tri- 
and tetraantennary type with proximal fucose were found in secreted 
vesicles of SKOV3 and OVM cells, as well as in the plasma membrane and 
microsomal fraction. SKOV3 cells were found to contain predominantly 
proximally fucosylated complex partially agalactosylated glycan structures 
in all fractions. Moreover, the terminal GalNAcβ4GlcNAc (LacdiNAc) motif 
was also found in SKOV3 secreted vesicles. OVM secreted vesicles 
contained predominantly complex intact glycans of the di-, tri- and 
tetraantennary types.  
 In conclusion, this research has contributed to the knowledge of 
protein glycosylation present in vesicles secreted by ovarian tumour cells. 
This information should provide the basis for further exploration of the 
mechanisms of protein sorting and exosome biogenesis. Moreover, the 
identification of specific glycoproteins and N-glycans in exosomes might 
open new perspectives in biomarker discovery and cancer vaccination. 
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Resumo 
 
 Exossomas são pequenas vesículas membranares secretadas por 
diversos tipos de células, incluindo células tumorais. Eles são formados 
intracelularmente, pela invaginação da membrana de compartimentos 
endossomais que dão origem aos corpos multivesiculares. A fusão dos 
corpos multivesiculares com a membrana plasmática resulta na libertação 
dos exossomas para o ambiente extracelular. Após internalização por 
outras células, os exossomas podem transferir proteínas e RNA entre 
células. Exossomas secretados por células tumorais podem promover a 
angiogénese, proliferação celular, invasão tumoral e evasão do sistema 
imunitário. Estas vesículas foram encontradas em fluidos biológicos, tais 
como, ascites e sangue, e como tal, podem ser usadas para identificar 
potenciais biomarcadores de doenças e também em vacinação. 
 Proteínas com glicosilação alterada encontram-se frequentemente 
associadas com o processo de tumorigénese; como tal, estruturas 
glicosídicas representam alvos ideais para o diagnóstico específico de 
tumores e para o desenvolvimento de novas estratégias terapêuticas anti-
tumorais. 
 Esta Tese visou a caracterização e investigação do papel biológico 
da N-glicosilação em proteínas presentes em exossomas secretados por 
células do carcinoma do ovário, com particular ênfase na glicoproteína 
desintegrina e metaloprotease ADAM10. 
 O Capítulo 2 descreveu a investigação do papel da N-glicosilação 
na localização intracelular, actividade e transporte para os exossomas da 
proteína ADAM10. Para alcançar esse objectivo foi utilizada a metodologia 
de mutagénese dirigida para construir mutantes em que os locais de N-
glicosilação foram individualmente eliminados: S269A, T280A, S441A, 
T553A. A análise por Western blot de células de carcinoma do ovário 
SKOV3, transfectadas estavelmente com o tipo selvagem ou com os 
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mutantes de N-glicosilação da ADAM10, mostrou que todos os potenciais 
locais de N-glicosilação se encontravam ocupados com oligossacáridos do 
tipo oligomanose ou complexo. O mutante T280A foi encontrado 
acumulado no reticulo endoplasmático, na forma precursora não 
processada da enzima, enquanto o mutante S441A mostrou um aumento 
na susceptibilidade à proteólise. O estudo da actividade in vivo da 
ADAM10 monitorizando a molécula de adesão celular L1 como substrato, 
em células HEK293 e em fibroblastos de ratinhos silenciados para a 
ADAM10, revelou que a mutação individual dos diferentes locais de N-
glicosilação da ADAM10 não aboliu por completo a actividade da enzima. 
Da mesma forma, todos os mutantes exibiram actividade proteolítica in 
vitro usando o péptido proTNF-alpha como substrato. No entanto, foi 
observada uma redução nos níveis de clivagem, especialmente com o 
mutante T280A. Por outro lado, todos os mutantes de N-glicosilação da 
ADAM10 que foram processados para a forma matura foram 
eficientemente transportados para os exossomas. No global, estes 
resultados mostram a importância da N-glicosilação no processamento, 
protecção contra a proteólise e actividade enzimática da ADAM10. 
 Os exossomas podem interagir e ser internalizados por células-
alvo, no entanto, os mecanismos envolvidos nesse processo ainda são 
pouco compreendidos. O Capítulo 3 mostrou, por microscopia de 
fluorescência, a internalização de exossomas de células SKOV3 marcados 
com succinimidil éster diacetato de carboxifluoresceína por células SKOV3, 
através de um mecanismo dependente de energia. A colocalização parcial 
com o marcador de endossomas EEA1 e a inibição com clorpromazina 
sugeriu o envolvimento da via de endocitose mediada por clatrina. Por 
outro lado, a inibição da internalização na presença de 5-etil-N-isopropil 
amiloride, citocalasina D e metil-beta-ciclodextrina sugeriu o envolvimento 
de outras vias endocíticas. Para além disso, foram necessárias, pelo 
menos parcialmente, proteínas presentes nos exossomas e na superfície 
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das células SKOV3 para a internalização, como mostrado pela diminuição 
nos níveis de internalização após tratamento com proteinase K. 
 A análise do perfil de glicosilação dos exossomas de células 
SKOV3, usando lectinas com diferentes especificidades, revelou que eles 
eram enriquecidos em glicoproteínas específicas com manose e ácido 
siálico. Essas glicoproteínas não se encontravam nos extractos celulares 
podendo constituir marcadores de exossomas. Adicionalmente, foi 
investigado o papel da glicosilação na internalização de exossomas. A 
remoção do ácido siálico levou a uma tendência para um aumento na 
eficiência da internalização, enquanto que a incubação com os 
monossacáridos D-galactose, α-L-fucose, α-L-manose, D-N-
acetiglucosamina e o dissacárido β-lactose reduziu a internalização para 
níveis comparáveis ao do controlo com D-glucose. 
 O Capítulo 4 visou a caracterização pormenorizada do perfil de N-
glicanos presentes em células do carcinoma do ovário. A análise detalhada 
da estrutura dos N-glicanos presentes nas vesículas secretadas, fracção 
microssomal e membrana plasmática de células SKOV3 e OVM foi 
efectuada por cromatografia de troca iónica de elevada “performance” com 
detecção amperométrica pulsada (HPAEC-PAD) e por espectometria de 
massa com “matrix assisted laser desorption/ionization time-of-flight” 
(MALDI-TOF-MS). Glicanos do tipo bi-, tri- e tetra-ramificados com fucose 
próxima foram encontrados nas vesículas secretadas pelas células SKOV3 
e OVM, bem como na membrana plasmática e fracção microssomal. Todas 
as fracções das células SKOV3 apresentaram, predominantemente, 
estruturas glicosídicas parcialmente agalactosiladas com fucose próxima. 
Para além disso, o motivo terminal GalNAcβ4GlcNAc (LacdiNAc) também 
foi encontrado nas vesículas secretadas pelas células SKOV3. As 
vesículas secretadas pelas células OVM apresentaram 
predominantemente glicanos intactos do tipo complexo bi-, tri- e 
tetraramificados. 
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 Em conclusão, este estudo contribuiu para o conhecimento da 
glicosilação de proteínas presentes em vesículas secretadas por células do 
carcinoma do ovário. Esta informação poderá fornecer uma base para a 
exploração futura dos mecanismos de selecção de proteínas e biogénese 
dos exossomas. Além disso, a identificação de glicoproteínas e N-glicanos 
específicos nos exossomas poderá abrir novas perspectivas na descoberta 
de biomarcadores e na vacinação contra o cancro.  
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Thesis Outline 
 
Exosomes are secreted by several cell types, including ovarian 
tumour cells and are found in biological fluids such as blood and malignant 
ascites. The role of these vesicles in tumour progression has been studied 
but the role of protein glycosylation is not known. 
The major objective of this work was to characterize and investigate 
the biological role of protein N-glycosylation from ovarian tumour derived 
exosomes. Furthermore, the role of N-linked glycans in ADAM10 
localization, activity and sorting to exosomes has also been investigated. 
This dissertation begins with a general introduction to ovarian 
cancer biology, which is followed by an overview about protein 
glycosylation, with focus on the N-glycosylation biosynthetic pathway and 
abnormal glycosylation properties found in cancer cells. Exosome 
biogenesis, composition and function are described in detail and particular 
relevance is given to tumour-derived exosomes as potential biomarkers 
and therapeutic targets. Finally, a brief characterization of the 
metalloprotease and disintegrin ADAM10 is given, including protein 
structure, activity and role in cancer. 
In Chapter 2, the role of N-linked oligosaccharides on ADAM10 
intracellular localization, activity and sorting to exosomes was investigated. 
Chapter 3 describes the mechanisms involved in the uptake of 
labelled exosomes from SKOV3 cells by SKOV3 cells. Furthermore, the 
glycosylation profile of these secreted vesicles was analysed by lectin blot 
using different lectins. 
In Chapter 4, the glycosylation of ovarian tumour secreted vesicles, 
microsomal and plasma membrane enriched fractions were compared by 
lectin blot analysis. The N-glycan structures from glycoproteins present in 
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these fractions were also analysed in detail by HPAEC-PAD and MALDI-
TOF-MS.  
Finally, Chapter 5 consists of a general discussion with future 
perspectives, and conclusions of the work presented in this Thesis.  
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1. General introduction 
 
 
1.1. Ovarian cancer 
 
Ovarian cancer is the leading cause of death from gynaecological 
malignancies in the Western world. The high death rate associated with this 
disease is mainly due to the absence of specific symptoms, rapid growth 
rate and to lack of an effective screening, and as a result most patients are 
diagnosed at an advanced stage when the disease is already disseminated 
throughout the abdominal cavity.  
Ovarian cancers are a heterogeneous group of neoplasms and are 
traditionally divided into three major categories according to their presumed 
histogenesis: sex cord-stromal, germ cell, and epithelial tumours. Epithelial 
ovarian tumours, which represent 90% of malignant ovarian tumours, are 
further grouped into histological types: serous, mucinous, endometrioid, 
clear cell, transitional cell tumours, carcinosarcoma, mixed epithelial 
tumour, undifferentiated cancers, and others (reviewed in Scully, 1987; 
Kaku et al., 2003). 
The biological mechanisms of transformation in ovarian cancer are 
poorly understood. Mutations in the BRCA1 and BRCA2 tumour suppressor 
genes are responsible for a great number of hereditary ovarian cancers 
(Holschneider and Berek, 2000), however, the majority of ovarian cancers 
are sporadic, in which the disease arises from a multistep process requiring 
a large number of genetic changes involving both activation of oncogenes 
and loss of tumour-suppressor genes (Cvetkovic, 2003).  
Ovarian cancers diagnosed while still limited to the ovaries (stage I), 
allow that 90% of patients can be cured with conventional surgery and 
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chemotherapy. Cure rates decrease substantially after tumour metastasis 
to the pelvic organs (stage II), the abdomen (stage III) or beyond the 
peritoneal cavity (stage IV) (Bast et al., 2009). Early detection of ovarian 
cancer might significantly improve the overall survival rate. Nevertheless, 
given the heterogeneity of the disease, it is unlikely that any single marker 
will be sufficiently sensitive to provide an effective initial screen. Probably, 
the combination of multiple serum markers may help achieve the sensitivity 
and specificity required for the screening of ovarian cancer (Badgwell and 
Bast, 2007).  
 
1.2. Protein glycosylation 
 
Glycosylation is the major post-translational modification of proteins 
and lipids and is estimated to be present in more than half of all proteins in 
nature. Glycosylation of proteins can be of the N- or O-linkage type 
depending on glycans site of attachment. An N-glycan is a sugar chain 
covalently linked via an N-acetylglucosamine (GlcNAc) residue to an 
asparagine (Asn) residue of a polypeptide chain within the consensus 
peptide sequence Asn-X-Ser/Thr. N-glycans share a common 
pentasaccharide core region and can be generally divided into three main 
types: high mannose, complex, and hybrid. An O-glycan is  typically linked 
to the polypeptide via an N-acetylgalactosamine (GalNac) residue to a 
serine (Ser) or threonine (Thr) residue and can be extended into a variety 
of different structural core classes (Varki et al., 2009).  
The function of the glycans presented in glycoconjugates can be 
crucial for the growth, development, and survival of cells and organisms. 
Glycans have been shown to participate in recognition events and host-
pathogen interactions such as bacterial and viral infections. They are 
involved in protein folding and sorting, vesicular trafficking, cell signalling, 
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cell adhesion and motility, organogenesis and immunological defence 
(reviewed in Varki, 1993; Ohtsubo and Marth, 2006). Additionally, 
glycosylation can affect protein plasma residence time, it provides steric 
protection from proteases, and it plays a role on enzyme activity, substrate 
targeting and specificity (reviewed in Skropeta, 2009). 
 
1.2.1. N-glycosylation 
 
The biosynthesis of N-linked oligosaccharides occurs in the 
endoplasmic reticulum (ER) and Golgi complex (Figure 1, A). During the 
synthesis of N-linked glycans a 14-saccharide “core” unit is assembled as a 
membrane bound dolichylpyrophosphate precursor by enzymes located on 
both sides of the ER membrane. The structure of this precursor is common 
to most eukaryotes and contains 3 glucose, 9 mannose, and 2 GlcNAc 
residues (Glc3Man9GlcNAc2). The completed core oligosaccharide is 
transferred from the dolichylpyrophosphate carrier to the nascent 
polypeptide chain, and is coupled through an N-glycosidic bond to the side 
chain of an asparagine residue. The oligosaccharyltransferase responsible 
for this transfer is a complex enzyme with its active site in the ER lumen 
and that recognizes a specific conformation of the glycosylation sequon 
(Asn-X-Ser/Thr), where X can be any amino acid except proline. Of all 
sequons, it has been estimated that 90% are glycosylated (Gavel and 
Heijne, 1990). Before exiting the ER, a terminal glucose, and mannose 
residues are removed from the N-glycan by ER glucosidases and 
mannosidases. When the glycoprotein moves to the Golgi complex, the 
glycan chains undergo further trimming of mannoses before further 
extension of the glycan branches. Subsequent step-wise adding of sugars 
to different positions of the extending glycan is catalyzed by a number of 
Chapter 1 
6 
glycosyltransferases, each adds a particular monosaccharide through a 
specific glycosidic bond (Helenius and Aebi, 2001; Varki et al., 2009). 
N-glycan structures are generally classified into three principal 
categories: high mannose, complex and hybrid (Figure 1, B), all of them 
share a common tri-mannosyl (Man3GlcNAc2) core structure. The high 
mannose glycans have 5 to 9 mannose (Man5–9GlcNAc2) sugars. Those 
with two GlcNAc’s attached to the tri-mannosyl core are called complex 
type. The hybrid type are a combination of high mannose and complex 
glycans, and have at least three mannose sugars, but only one GlcNAc on 
one nonreducing mannose (Helenius and Aebi, 2001; Varki et al., 2009). 
The removal of N-glycans from proteins, either individually or in 
combination has revealed their role in many cellular processes (reviewed in 
Skropeta, 2009) and total inhibition of N-glycosylation lead to death in early 
embryogenesis (Marek et al., 1999). Nevertheless, lysosomal targeting is 
probably the best characterized role of N-linked glycosylation, the binding 
of mannose 6-phosphate on N-linked oligosaccharides in the trans-Golgi 
mediate the targeting of glycoproteins to the lysosome. Attachment of N-
glycans is also an essential requirement for some glycoproteins to exit the 
secretory pathway. The ER is known to have a primary quality control 
function by ensuring the fidelity and proper native conformation of proteins 
that cross this compartment (Helenius and Aebi, 2001).  
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Figure 1.  N-glycosylation processing and representation of the different N-
glycan types. (A) N-linked oligosaccharides processing involves a series of steps 
that occur in different compartments of the secretory pathway. (B) Schematic 
representation of high mannose, complex and hybrid N-glycans. ER, 
endoplasmatic reticulum; TGN, trans-Golgi network. Adapted from Taylor and 
Drickmer, 2006; Varki et al., 2009.  
 
 
1.2.2. O-glycosylation  
 
In O-linked glycosylation, monosaccharide residues are sequentially 
added onto the protein, in the Golgi apparatus. There is no consensus 
sequence and there are several possible O-glycosidic linkages.  
The main forms of O-glycans on higher eukaryotic secretory 
proteins are mucin-type glycans and proteoglycans (Ungar, 2009). Mucin 
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synthesis starts with the addition of an GalNAc residue to a Ser/Thr side 
chain. This is followed by the formation of one of four distinct core 
structures by the addition of Gal and GlcNAc residues in various linkages. 
These core structures are the basis for the synthesis of a large variety of 
different glycans containing largely Gal, GlcNAc and NeuAc sugars. The 
hallmark of proteoglycans is the extensive modification of sugar residues 
with sulfate to create charged surfaces that interact with the extracellular 
matrix. Their glycan chains are linked to serine hydroxyls through a 
tetrasaccharide comprising xylose-Gal-Gal-glucuronic acid (GlcA) residues. 
The main proteoglycan oligosaccharides are repetitive structures formed by 
GlcNAc-GlcA or GlcNAc-iduronic acid dimers often containing N-linked (on 
GlcNAc only) or O-linked sulfate groups (Ungar, 2009). 
 
1.2.3. Glycosylation in cancer 
 
Glycosylation alterations are typical for all kinds of cancers, 
including ovarian cancer, and include increased and/or reduced expression 
of certain structures, the persistence of incomplete or truncated structures, 
the accumulation of precursors, and the appearance of novel structures. 
Some of these alterations affect tumour progression by increasing cells 
detachment from the extracellular matrix, cell motility, adhesion to activated 
endothelial cells or metastasis. Glycoconjugates released by tumours have 
been detected in the blood stream and have been used in diagnosis as 
cancer markers and targets for therapeutic approaches (Varki et al., 2009; 
Peracaula et al., 2008). 
Described changes in glycosylation comprise increased β1–
6GlcNAc branching of N-glycans; changes in the amount, linkage, and 
acetylation of sialic acids; reexpression of N-glycolylneuraminic acid; 
overexpression of specific carbohydrate antigens that lead to terminal 
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structures like sialyl-Lewisx (sLex), sialyl-Lewisa (sLea), or polysialic acid; 
expression of selectin ligands; altered expression and enhanced shedding 
of glycosphingolipids; increased expression of galectins and 
polylactosamines; altered expression of the ABH(O) blood-group-related 
structures; alterations in sulfation of GAGs; increased expression of 
hyaluronan; or loss of expression of glycophospholipid anchors. In many 
cases the formation of these aberrant structures depends on altered 
regulation of one or more key glycosyltransferases or glycosidases (Varki 
et al., 2009; Peracaula et al., 2008). 
The most widely used tumour marker in ovarian cancer is CA125 
(MUC16), a large mucin protein containing both N- and O-glycosylation. 
CA125 is increased in 80-90% of patients with advanced stage ovarian 
cancer, but it is only elevated in 50% of patients with stage I disease. 
Moreover, CA125 lacks specificity since it is not expressed in all forms of 
ovarian cancer and might be elevated in various benign conditions (Gupta 
and Lis, 2009; Jelovac and Armstrong, 2011). Since aberrant glycosylation 
also occurs in ovarian cancer, several studies have been performed to 
identify abnormal oligosaccharides present on the glycoproteins of ovarian 
cancer cell lines and human serum from ovarian cancer patients. Cell 
surface antigens such as Lewisy, sLex, sialyl-Tn, and Tn antigens were 
found in primary ovarian carcinomas and their metastases (Davidson et al., 
2000). Furthermore, mucinous tumours were found to intensively express 
sialyl-Tn, Lewisa, and sLea, whereas serous and endometrioid tumours 
strongly expressed Lewisy and H-type 2 antigen (Federici et al., 1999). 
Bisecting glycans have also been described in tissues of endometrioid 
ovarian cancers (Abbott et al., 2008).  
Specific changes in the serum of ovarian cancer patients include 
increase of core fucosylated, agalactosylated complex type diantennary 
glycans originated from immunoglobulin G, along with the sLex determinant 
(Saldova et al., 2007). Alterations in fucosylation and branching in α1-acid 
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glycoprotein have also been proposed as potential biomarkers of ovarian 
cancer (Imre et al., 2008). Furthermore, an increase in sialylation with a 
shift in sialic acid linkage from α2,3- to α2,6- was observed in ovarian 
cancer serum glycoproteins (Saldova et al., 2007). 
Alterations in the functions of the glycosyltransferases responsible 
for the formation of these antigens are also a consequence of ovarian 
tumour development and have been reported in several studies. These 
modifications include alterations in mRNA levels of α2,3- and α2,6-
sialyltransferases in the tissues of serous ovarian cancer (Wang et al., 
2005), elevated expression of N-acetylglucosaminyltransferase V in 
mucinous ovarian carcinoma tissues (Takahashi et al., 2009), elevated α6-
fucosyltransferase in serous adenocarcinomas (Takahashi et al., 2000), 
and elevated α3/4-fucosyltransferase activities in ovarian cancer 
(Chandrasekaran et al., 1992). 
Ovarian carcinoma cell lines, SKOV3, GG, OVM, and m130 were 
also characterized with respect to their glycosylation using anti-
carbohydrate antibodies and lectins (Escrevente et al., 2006). These cell 
lines contained variable amounts of Lewis carbohydrate motifs and 
glycoproteins recognized by Concanavalin A, a lectin that binds α-mannosyl 
containing-branched glycans predominantly of the high mannose followed 
by hybrid and diantennary complex structures to a lower extent, and 
Sambucus nigra lectin that binds structures containing terminal α2,6-linked 
sialic acid. In addition, structure analysis of the N-linked glycans from total 
glycoproteins derived from SKOV3 ovarian carcinoma cells confirmed the 
abundance of high mannose and proximally fucosylated complex partially 
agalactosylated glycan structures as well as the presence of the LacdiNAc 
motif (Machado et al., 2011). 
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1.3. Exosomes 
 
Exosomes are small microvesicles that are released into the 
extracellular environment by a variety of different cells. The release of 
exosomes has been described for the first time for maturing reticulocytes 
(Johnstone et al., 1987) but since then it has been observed for a multitude 
of other hematopoietic cells, including B cells (Raposo et al., 1986), 
dendritic cells (Théry et al., 1999), mast cells (Raposo et al., 1997), and T-
cells (Blanchard et al., 2002). In addition, they can be released by cells with 
different origins such as intestinal epithelial cells (van Niel et al., 2001), 
kidney cells (Hoorn et al., 2005), neurons (Faure et al., 2006) and tumour 
cells (Andre et al., 2002). Furthermore, exosomes have been detected in 
various bodily fluids such as blood plasma (Caby et al., 2005), urine 
(Pisitkun et al., 2004), saliva (Ogawa et al., 2008), breast milk (Admyre et 
al., 2007), and malignant pleural effusions (Bard et al., 2004). 
Exosomes from different origins all share certain common 
characteristics, including size (40-100 nm), structure (lipid-bilayer), shape 
(cup-shaped morphology), density in sucrose gradient (1.13-1.19 g/ml) and 
general protein and lipid composition (Simons and Raposo, 2009; Théry et 
al., 2009). 
Exosomes can be isolated based on their size, density and/or 
biochemical properties. The most commonly used procedure is based on 
differential sedimentation and involves several centrifugations to remove 
dead cells, large debris and other cellular contaminants, followed by a final 
high-speed ultracentrifugation to pellet small vesicles. This pellet contains 
exosomes, which can be further purified by a sucrose density gradient 
(Théry et al, 2006) to remove contaminating vesicles of distinct sizes and 
densities that are also produced by healthy (Figure 2) or apoptotic/ dying 
cells (Théry et al., 2009). Other methods including membrane ultrafiltration 
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(Lamparski et al., 2002) and immunoaffinity capture (Clayton et al., 2001) 
can also be used depending on the sample source and applications 
intended. 
 
1.3.1. Biogenesis and secretion 
 
The uptake of material from the exterior of the cells occurs via 
endocytosis. The endocytic vesicles are then transported to early 
endosomes and recycled back to the plasma membrane, or delivered to 
late endosomes together with other proteins (Figure 2). In late endosomes, 
proteins are sorted into intraluminal vesicles by inward budding of the 
limiting membrane into the endosomal lumen, forming multivesicular 
endosomes, classified on the basis of their morphology as multivesicular 
bodies (MVBs). Consequently, proteins are incorporated into the 
invaginating membrane, thus maintaining the same topological orientation 
as the plasma membrane while cytosolic components are engulfed (Février 
and Raposo, 2004).  
The mechanisms underlying sorting of proteins into intraluminal 
vesicles at the endosomal-limiting membrane are largely unknown. One 
mechanism described involves the recognition of ubiquitinated proteins by 
the Endosomal Sorting Complex Required for Transport (ESCRT). The 
ESCRT machinery is organized into four heteromeric protein complexes. 
The ESCRT-0, -I and –II complexes recognize and sequester ubiquitinated 
proteins in the endosomal membrane, whereas the ESCRT-III complex 
seems to be responsible for membrane budding (reviewed in Lakkaraju and 
Rodriguez-Boulan, 2008; Simons and Raposo, 2009). However, some 
proteins present in the exosomes are not ubiquitinated, suggesting that 
other mechanisms such as oligomerization or partitioning of protein into 
lipid raft domains may be involved (de Gassart et al., 2003; Lakkaraju and 
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Rodriguez-Boulan, 2008; Schorey and Bhatnagar, 2008). Recently, an 
ESCRT-independent mechanism of protein sorting into MVBs involving the 
sphingolipid ceramide has been described (Trajkovik et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Exosome biogenesis and different types of membrane vesicles. 
Membrane proteins are internalized and delivered to early endosomes. In early 
endosomes, the proteins can be recycled to the plasma membrane or delivered to 
late endosomes. Proteins are sorted to intraluminal vesicles by budding of the 
endosomal limiting membrane into the endosomal lumen, forming multivesicular 
endosomes. Multivesicular endosomes can dock and fuse with the plasma 
membrane resulting in exosomes (40-100 nm) secretion. Some viruses, such as 
retroviruses, hijack the exosomal machinery and are secreted by the same 
mechanism. Microvesicles (100-1000 nm) and membrane particles (50-80 nm) can 
also be secreted by cells by direct budding from the plasma membrane into the 
extracellular space. Exosome-like vesicles (20-50 nm) are also thought to originate 
from internal multivesicular compartments, although the nature of these 
compartments is not clear. Adapted from Février and Raposo, 2004; Théry et al., 
2009. 
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In a final step, multivesicular endosomes can either fuse with 
lysosomes for protein degradation or with the plasma membrane, resulting 
in the release of exosomes (Figure 2). The mechanism that leads to 
exosomes secretion, though still poorly understood, appears to involve two 
Ras family monomeric proteins Rab27A and Rab27B (Ostrowski et al., 
2010). 
In addition to exosomes other vesicles may be secreted from 
mammalian cells and they have been classified based on their biogenesis 
and physiochemical properties, namely diameter (Figure 2) (Théry et al., 
2009). 
 
1.3.2. Composition 
 
Exosomes contain a variety of molecules, including proteins, RNA 
and lipids reflecting the cell type from which they originate and possibly 
their functional role.  
Although the protein content of exosomes varies depending on their 
source, the proteomic analysis of exosomes from a wide variety of cells and 
body fluids has identified several proteins that are well conserved and are 
commonly used as exosomal markers. Nearly all exosomes contain 
proteins involved in membrane transport and fusion (RabGTPases, 
annexins, flotillin), in MVBs biogenesis (Alix, TSG101), metabolic enzymes 
(peroxidases, pyruvate and lipid kinases) and cytoplasmic proteins (tubulin, 
actin). Moreover, exosomes are enriched with heat shock proteins (hsp70 
and 90), integrins and tetraspanins (CD63, CD9, CD81) (reviewed in 
Simpon et al., 2008, Schorey and Bhatnagar, 2008; Simons and Raposo, 
2009; Mathivanan and Simpson, 2010) and were shown to carry active 
proteases, such as ADAM10 and ADAM17 (Stoeck et al., 2006). 
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Recent studies have demonstrated that exosomes also carry and 
deliver mRNA and small RNAs, including microRNA (Valadi et al., 2007; 
Skog et al., 2008). A compendium of exosomes RNAs and proteins is 
available at “Exocarta” (http://exocarta.ludwig.edu.au). 
Moreover, exosomes display a specific lipid composition different 
from the parental cells. They are particularly enriched in raft-lipids such as 
cholesterol, sphingolipids, ceramide and glycerophospholipids with long 
and saturated fatty-acyl chains (Subra et al., 2007; Trajkovik et al., 2008). 
 
1.3.3. Function 
 
Exosomes were originally observed as a mechanism to remove 
unnecessary proteins, namely the transferrin receptor during reticulocytes 
maturation (Johnstone et al., 1987). However, since then many other 
functions have been proposed such as intercellular communication, 
induction of immune responses, and transfer of infectious agents, among 
several others. 
The ability of exosomes to interact with cells has important 
biological implications, such as cell-cell communication, and the delivery of 
proteins and genetic material conferring new functional properties to the 
recipient cells. Several types of interaction between exosomes and cells 
have already been proposed based on indirect evidence and in vitro 
studies. Exosomes can associate with the plasma membrane through 
ligand-receptor interactions (Théry et al., 2009) or lipids, such as 
phosphatidylserine (Keller et al., 2009). The process of internalization can 
occur through direct fusion of the exosomes with the plasma membrane, 
releasing the exosomal content into the cell cytoplasm. Alternatively, 
exosomes can enter the cells by receptor-mediated endocytosis and later 
fuse with the limiting membrane of the endosome releasing the exosomal 
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content to be recycled to the cell surface or to be degraded in the lysosome 
(Théry et al., 2009; Coccusi et al., 2009). Exosome uptake was shown to 
occur via clathrin-mediated endocytosis in dendritic cells (Morelli et al., 
2004), as well as phagocytosis in monocytes and macrophages (Feng et 
al., 2010). 
One of the most studied roles of secreted exosomes is their 
powerful effect on the immune system. Exosomes secreted from different 
sources can have both an activating or a tolerogenic or even inhibitory 
effect on immune cells. In general, exosomes produced by antigen-
presenting cells such as dendritic cells, macrophages and B cells are 
immune activating. They activate directly or indirectly immune effector 
mechanisms such as cytotoxicity, antibody and cytokine production, and 
priming of T cells. On the other side, exosomes produced by epithelial cells 
and the great majority of tumours are immune inhibitory, playing an 
important role on tumour dissemination (Théry et al., 2009). 
Exosomes can also participate in the propagation of infectious 
agents. Février et al. showed that the prion protein and the scrapie forms of 
the protein (PrPc and PrPsc, respectively) can be secreted in association 
with exosomes (Février et al., 2005). Moreover, a role for exosomes in the 
intercellular trafficking of human immunodeficiency virus (HIV-1) infectivity 
has also been suggested (Gould et al., 2003; Wiley and Gummuluru, 2006; 
Izquierdo-Useros et al., 2008). 
Furthermore, exosomes have been proposed as a novel platform for 
ADAM-mediated cleavage. The proteolysis of cell adhesion transmembrane 
molecules like L1 and CD44 by ADAMs can occur in MVBs and exosomes, 
in addition to the plasma membrane (Stoeck et al., 2006; Keller et al., 
2006).  
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1.3.4. Tumour cell-derived exosomes  
 
The biological significance of exosomes secretion by tumours, and 
the presence of these vesicles in malignant effusions such as ascites, is not 
clear. Tumours reported to release exosomes include cancers of the ovary, 
breast, oral cavity, colorectum, brain, bladder, prostate, and melanomas 
(reviewed in Zhang and Grizzle, 2011).  
Tumour-secreted vesicles, including exosomes, can contribute to 
tumour invasion and progression by transferring aggressive cancerous 
phenotypes (Al-Nedawi et al., 2008), modifying the tumour 
microenvironment (Castellana et al., 2009), conferring multi-drug resistance 
(Shedden et al., 2003; Safaei et al., 2005), and promoting angiogenesis, 
tumour growth and metastasis (reviewed in Muralidharan-Chari et al., 
2010).  
Some reports point to a role of cancer exosomes in immune 
activation (reviewed in Théry et al., 2009). Wolfers et al, (Wolfers et al., 
2001) showed that tumour-derived exosomes were able to transfer 
antigens from tumour cells to dendritic cells and, therefore, function in 
antigen-cross presentation on syngeneic and allogeneic established mouse 
tumours. However, recent studies point to the increasing evidence that 
cancer exosomes might instead suppress the immune system facilitating 
tumour growth and invasion (reviewed in Valenti et al., 2007; Zhang and 
Grizzle, 2011). This can occur through several mechanisms such as 
induction of myeloid-derived suppressor cells (Iero et al., 2008) and 
inhibition of dendritic cell maturation (Yu et al., 2007) or T cell function 
(Clayton et al., 2007).  
The role of exosomes in immune suppression and ovarian tumour 
progression has been investigated. Ascites-derived exosomes induced 
apoptosis of cells of the immune system (Peng et al., 2011) and resulted in 
Chapter 1 
18 
the growth of an ovarian carcinoma in vivo, after systemic administration 
(Keller et al., 2009). Moreover, exosomes derived from ovarian carcinoma 
cell lines and patient’s ascites were shown to act as platforms for 
ectodomain shedding, being an important source of soluble adhesion 
molecules like L1 and CD44 that could regulate tumour cell function in an 
autocrine/paracrine fashion (Gutwein et al., 2005; Stoeck et al., 2006), and 
exhibited gelatinolytic activity, responsible for increasing tumour invasion 
into the stroma (Runz et al., 2007. Exosomes derived from human ovarian 
carcinoma cells have also been implicated in drug resistance, acting as a 
mechanism of efflux for the drug cisplatin (Safaei et al., 2005). 
 
1.3.5. Exosomes in diagnosis and therapeutics 
 
The presence of exosomes in biological fluids such as, blood 
plasma (Caby et al., 2005) and urine (Pisitkun et al., 2004), and the fact 
that they can be easily collected using non-invasive methods holds 
significant potential. Exosomes can be used for obtaining novel and 
complex sets of biomarkers for the early detection and diagnosis of 
diseases, for determining prognosis, and for therapeutic interventions such 
as the development of vaccines. 
Urinary exosomes have been extensively studied having in view the 
discovery of potential disease biomarkers of bladder (Welton et al., 2010) 
and prostate cancer (Nilsson et al., 2009). Similarly, exosomes collected 
from blood plasma have also been investigated. MicroRNA profiling of 
circulating exosomes was explored as a diagnostic marker for biopsy 
profiling and to screen asymptomatic populations with ovarian (Taylor and 
Gercel-Taylor, 2008) and lung cancer (Rabinowits et al., 2009).  Blood 
derived-exosomes of women with ovarian cancer contained high levels of 
claudin-4, a membrane protein whose expression is elevated in ovarian 
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cancer (Li et al., 2009), and exosomes derived from sera and malignant 
ascites showed the presence of tumour progression related proteins (L1, 
ADAM10, CD24, and EpCAM) (Gutwein et al., 2005; Runz et al., 2007). 
Since both tumour and immune cells are able to secrete exosomes, 
the application of these vesicles in immunotherapy has become a 
promising area of research in cancer (reviewed in Tan et al., 2010), 
infectious (Beauvillain et al., 2009) and autoimmune diseases (Kim et al., 
2005). The ability of exosomes released from dendritic cells, pulsed with 
tumour antigens to stimulate T-cells and to induce the eradication of 
tumours in mice (Zitvogel et al., 1998) has led to their use as therapeutic 
agents for the stimulation of anti-tumoral immune responses. Exosomes 
have already been used in phase I clinical trials with patients showing 
advanced stage melanomas (Escudier et al., 2005), non-small cell lung 
carcinomas (Morse et al., 2005), and colorectal cancer (Dai et al., 2008).  
 
 
1.4. ADAM10 
 
ADAM (A Disintegrin And Metalloprotease) 10 is a type I 
transmembrane glycoprotein that belongs to the ADAMs family and to the 
zinc-dependent metalloproteinases (metzincins) superfamily.  
Mammalian ADAM10 was originally isolated from bovine brain, 
based on its ability to cleave myelin based protein in in vitro preparations 
(Chantry et al., 1989), but later work showed that it is widely expressed 
among different tissues and several species. 
The gene locus for human ADAM10 was matched to chromosome 
15 at position 15q21.3-q23 (Yamazaki et al., 1997) and codes for a protein 
with 748 amino acids that has four potential N-glycosylation sites, N267, 
N278, N439 and N551 (Figure 3). 
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ADAM10 is synthesized in the rough endoplasmic reticulum and is 
maturated in the late Golgi compartments. Subcellular localization analysis 
revealed that human ADAM10 is mainly located at the plasma membrane 
(Gutwein et al., 2003) but it also colocalizes with Golgi markers and it was 
found in secreted vesicles identified as exosomes (Lammich et al., 1999; 
Gutwein et al., 2003). 
The major role of ADAM10 is the proteolytic cleavage of 
transmembrane proteins with important physiological and pathological 
roles. The severe phenotype of ADAM10-/- embryos implies that ADAM10 
has a crucial role on early vertebrate embryogenesis. In fact, the knockout 
of ADAM10 in mice is embryonic-lethal at 9.5 days and showed evidence of 
pronounced defects of the developing central nervous system, somites, and 
cardiovascular system due to disrupted Notch signalling (Hartmann et al., 
2002).  
 
1.4.1. Structure 
 
ADAM10 is characterized by a conserved domain structure common 
to other ADAMs consisting of an N-terminal signal sequence that directs 
the protein to the secretory pathway, followed by a prodomain, a 
metalloprotease and disintegrin domains, a cystein-rich region, a 
transmembrane domain, and finally an SH3-enriched cytoplasmic tail 
(Wolfsberg et al., 1995) (Figure 3). 
ADAMs structural domains have been shown to play specific roles. 
ADAM10 prodomain keeps the metalloprotease inactive, through a “cystein 
switch” mechanism. The Zn2+ is coordinated by three histidines in the 
catalytic site, the free sulfhydryl group of the cystein residue provides a 
fourth coordination site and inhibits the entrance of the water molecule 
which is responsible for hydrolysis (Schlondorff and Blobel, 1999). The 
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catalytically active form of ADAM10 is generated by proteolytic removal of 
the prodomain by proprotein convertases furin and/or PC7 in the Golgi 
compartments (Anders et al., 2001). Evidence suggests that the prodomain 
also plays an important role as a chaperone in the proper folding of the 
proenzyme in the ER, particularly the metalloprotease domain (Fahrenholz 
et al., 2000). More recently, the isolated prodomain of ADAM10 was shown 
to act as a potent, selective inhibitor of the active mature form of the protein 
(Moss et al., 2007). 
The metalloprotease domain is well conserved among ADAMs and 
is similar in sequence to the snake venom metalloproteases. Although not 
all ADAMs yield metalloprotease activity, ADAM10 contains the consensus 
active site sequence HEXGHNLGXXHD, which binds the zinc ion in an 
appropriate configuration around the glutamate residue required for 
catalytic activity.  
 
 
 
Figure 3.  Domain structure of ADAM10. It consists of a signal peptide (S), a 
prodomain (Pro), a metalloprotease domain (MP), a disintegrin domain (Dis), a 
cystein-rich region (Cys-rich), a transmembrane region (TM), and a cytoplasmic tail 
(Cyt tail). ADAM10 has four potential N-glycosylation sites, three located in the 
metalloprotease domain, N267, N278 and N439, and one in the disintegrin domain, 
N551.  
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ADAMs disintegrin and cystein-rich domains were described as 
being directly involved in cell-cell adhesion processes through interactions 
with integrins and other receptors (White, 2003). Although no disintegrin 
activity has been reported for ADAM10, Janes et al. demonstrated that 
these domains are essential for ephrinA5/EphA3 substrate recognition 
(Janes et al., 2006). The formation of the ephrinA5/EphA3 complex creates 
a high affinity binding site for the cysteine-rich domain of ADAM10 which 
leads to a conformational switch that consents ADAM10 metalloprotease 
domain to cleave EphA5 in trans. 
ADAMs cytoplasmic tails were proposed to be involved in the 
regulation of the metalloprotease activity, oligomerization, signalling and/or 
control of maturation and subcellular localization. ADAMs tails contain 
binding site motifs for SH3 domain-containing proteins and potential sites 
for phosphorylation. There are a number of adaptor proteins such as 
MAD2, Lck, Eve-1, PACSIN3 and synapse associated protein-97 with 
binding capacity to the cytoplasmic tail of ADAM10 (reviewed in Edwards et 
al., 2008). Moreover, a proline-rich stretch in the cytoplasmic domain of 
ADAM10 has been shown to be important for the correct basolateral 
localization of the protein in polarized epithelial cells promoting is 
metalloprotease activity (Wild-bode et al., 2006). Similarly, the binding of 
synapse associated protein-97 to ADAM10 cytoplasmic tail is also 
responsible for the correct localization of ADAM10 in synaptic membranes 
(Marcello et al., 2007). 
 
1.4.2. Activity 
 
The metalloprotease activity of ADAM10 is responsible for the 
proteolytic cleavage of several transmembrane proteins and release of their 
extracellular domain. This process is referred to as ectodomain shedding 
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and occurs both constitutively and in response to a variety of stimuli, 
including intracellular calcium concentration, phorbol esters and protein 
kinase C activation (Pandiella and Massague, 1991; Reiss and Saftig, 
2009).  
ADAM10 has more than 40 known protein substrates with important 
roles in development, cell signalling and disease pathologies, such as 
central nervous system disorders, inflammation and cancer (Figure 4) 
(Pruessmeyer and Ludwig, 2009). ADAM10 substrates include the cell 
adhesion molecule L1 (Mechtersheimer et al., 2001), pro-tumour necrosis 
factor α (Lunn et al., 1997), type IV collagen (Millichip et al., 1998), amyloid 
precursor protein (APP) (Lammich et al., 1999), ephrin-A2 (Hattori et al., 
2000), epidermal growth factor receptor (EGFR) (Yan et al., 2002), Notch 
(Dallas et al., 1999; Hartmann et al., 2002), pro-heparin-binding epidermal 
growth factor (Lemjabbar and Basbaum, 2002),  fractalkine (Hundhausen et 
al., 2003), CD44 (Nagano et al., 2004), N-cadherin (Reiss et al., 2005), 
betacellulin (Sanderson et al., 2005), and the low-affinity immunoglobulin E 
receptor CD23 (Weskamp et al., 2006), among others. 
 ADAM10 mediated proteolysis leads to the release of soluble 
factors like growth factors and chemokines, and is associated with 
extracellular signalling events. The released peptides can bind to their 
receptors and mediate signals in an autocrine or paracrine fashion. 
Moreover, ADAM10 mediated shedding can also play a role in intracellular 
signalling by regulated intramembrane proteolysis (RIP) (Brown et al., 
2000). The ectodomain shedding of transmembrane proteins can promote 
further proteolysis of the remaining transmembrane fragment by the γ-
secretase complex, for type I transmembrane proteins, or by the signal 
peptide peptidase like proteins (SPPLs), for type II transmembrane 
proteins, leading to the intracellular release of soluble substrate fragments, 
which might be translocated into the nucleus leading to the transcriptional 
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activation of target genes (Reiss et al., 2005, Maretzki et al., 2005; Martin 
et al., 2008).   
Besides signalling functions, ADAM10-mediated ectodomain 
shedding is also an important mechanism to regulate cell surface proteins 
like cell adhesion molecules and to inactivate receptors (reviewed in Reiss 
et al., 2008). Recently, it has also been proposed that ADAM10 may 
function itself as a signalling protein in addition to its role as protease. 
ADAM10 can undergo ectodomain shedding by ADAM9 and ADAM15 
followed by γ-secretase intramembrane proteolysis and translocation of 
ADAM10 intracellular domain into the nucleus where it is thought to be 
involved in gene regulation (Parkin and Harris, 2009; Tousseyn et al., 
2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. ADAM10 substrates. ADAM10 substrates have important functions in 
central nervous system, cancer and inflammation.  
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The factors that determine the substrate selectivity of ADAM10 are 
still not fully understood. Substrates have highly variable cleavage sites and 
there are no identified cleavage sequences. Moreover, many of ADAM10 
substrates are also cleaved by other proteases, such as ADAM17 that 
shares high homology both in sequence and in substrate specificity with 
ADAM10. There is evidence that localization of both enzyme and substrate 
at particular subcellular microdomains is important for recognition and 
cleavage (Tellier et al., 2006). The secondary structure of the substrate 
justamembrane stalk is also an important factor for recognition (Seals and 
Courtneidge, 2003) and recent studies suggest that ADAM10 recognize 
preferentially cleavage sequences with large residues, primarily leucine, but 
also aromatic residues, while ADAM17 prefers smaller aliphatic residues 
(Caescu et al., 2009). 
Regulation of ADAMs activity might occur at different levels, such as 
transcriptional control, alternative splicing, post-translational modifications, 
interaction with other proteins, cellular localization, and substrate 
availability (reviewed in Huovilla et al., 2005). Furthermore, ADAM10 
activity can also be inhibited by tissue inhibitors of matrix 
metalloproteinases (TIMPs) 1 and 3 (Amour et al., 2000). More recently, 
synthetic inhibitors have also been developed mainly to be used as 
therapeutic agents to block ADAM10 activity in cancer (Moss et al., 2008). 
 
1.4.3. Role in cancer 
 
The sheddase activity of ADAM10 plays an important role in cellular 
signalling pathways and is critical for the survival of cancer cells. ADAM10 
was found upregulated in several tumours, such as uterine, and ovarian 
carcinomas (Fogel et al., 2003), human haematological malignancies (Wu 
et al., 1997), neuroblastomas (Yavari et al., 1998), prostate cancer 
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(McCulloch et al., 2004), gastric carcinoma cells (Tanida et al., 2004), colon 
cancers (Gavert et al., 2005) and oral squamous cell carcinoma (Ko et al., 
2005).  
ADAM10 contributes to tumorigenesis and metastasis through 
cleavage and activation of several membrane proteins such as growth 
factors and cell adhesion molecules, and by regulating the adhesion and 
motility of cells, as a result of its role on extracellular matrix degradation 
(reviewed in Reiss et al., 2006). ADAM10-mediated L1 release was 
reported to enhance tumour dissemination by increasing cell migration in 
ovarian and uterine carcinomas (Fogel et al., 2003). Moreover the 
ectodomain shedding of cell adhesion molecules like L1 and CD44 can 
enable cells to escape from the surrounding tissue and mediate cell 
signalling that can promote cell proliferation, survival, and motility (Gutwein 
et al., 2003; Nagano et al., 2004).  
As mentioned before, ADAM10 can also be found in secreted 
vesicles, identified as exosomes (Gutwein et al., 2003). Moreover, ADAM10 
present in exosomes from ovarian carcinoma cells and ascites fluid was 
found to be functionally active and able to cleave both L1 and CD44 
(Stoeck et al., 2006). These findings suggest that exosomes serve as a 
major platform for ectodomain shedding and as a vehicle for the export of 
soluble molecules that might have a role on tumour progression. 
Since ectodomain shedding has been implicated as a pathological 
mechanism in cancer, ADAM10 inhibition has been explored as a target for 
cancer therapeutic drugs. Several inhibitors for ADAM10 have been 
described, but the lack of selectivity has contributed to adverse side effects 
and to the failure in clinical trials (reviewed in Reiss et al., 2006). Moreover, 
ADAM10 inhibition could have a profound negative effect in situations 
where ADAM10-mediated cleavage has a protective role, for example in 
Alzheimer’s disease where ADAM10 cleavage of APP leads to a decrease 
in amyloide plaque formation.  
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1.5. Aims of this Thesis work 
 
 
 Exosomes are small membrane vesicles that are secreted by 
several cell types, including ovarian tumour cells, and have been found in 
biological fluids such as blood and malignant ascites. They can contribute 
to tumour invasion and progression by several mechanisms, and they are 
potential targets for the discovery of new disease biomarkers and for 
therapeutic interventions such as the development of vaccines. 
Glycosylation is one of the most important post-translational 
modifications and alterations in cell surface glycosylation are often related 
to malignant transformation. 
To date, little was known about the N-glycosylation profile of 
glycoproteins that are sorted to exosomes. The major goal of this work was 
to characterize and investigate the biological role of N-glycosylation from 
proteins present in exosomes of ovarian tumour cell lines. Furthermore, the 
glycoprotein metalloprotease ADAM10 has been studied in detail. 
 ADAM10 is a transmembrane protein with four potential N-
glycosylation sites that is found in exosomes secreted from ovarian 
carcinoma cell lines. The first objective of this thesis work was to mutate 
each individual N-glycosylation site of ADAM10 and to understand the role 
played by N-glycosylation on ADAM10 intracellular localization, in vivo and 
in vitro activities. Furthermore, the presence of wild-type and mutant forms 
of ADAM10 in exosomes from ovarian carcinoma cells was also monitored, 
in order to evaluate if N-glycosylation site occupancy was required for 
ADAM10 sorting to exosomes. 
 The mechanisms of exosomes interaction and uptake by target cells 
are still poorly understood. Therefore, the second objective consisted of 
exploring the mechanisms of internalization of labelled exosomes by 
SKOV3 ovarian tumour cells. Several endocytic pathways were explored 
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using endocytosis inhibitors and colocalization studies by 
immunofluorescence microscopy. Furthermore the roles of cell surface 
proteins and exosomes surface proteins, as well as, oligosaccharides were 
investigated in the uptake. In addition, the glycosylation profile of the 
exosomes was analysed and compared with total cellular extracts using 
lectins with different specificities.  
Since the exosomes had specific glycosylation patterns, as detected 
with lectins, the third objective consisted of the detailed structure analysis 
of the N-glycans from the secreted vesicles of SKOV3 and OVM ovarian 
carcinoma cell lines, as well as plasma membrane and microsomal 
fractions. The techniques used were HPAEC-PAD and MALDI-TOF-MS. 
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Functional role of N-glycosylation from ADAM10 
in processing, localization and activity of the 
enzyme 
 
The majority of the work presented in this chapter has been included in the 
following manuscript: 
 
Escrevente C, Morais VA, Keller S, Soares CM, Altevogt P, Costa J (2008). 
Functional role of N-glycosylation from ADAM10 in processing, localization and 
activity of the enzyme. Biochim Biophys Acta. 1780: 905-13.  
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2. Functional role of N-glycosylation from ADAM10 in 
processing, localization and activity of the enzyme 
 
 
2.1. Summary 
 
A disintegrin and metalloprotease 10 (ADAM10) is a type I 
transmembrane glycoprotein with four potential N-glycosylation sites (N267, 
N278, N439, and N551) that cleaves several plasma membrane proteins. In 
this work, ADAM10 was found to contain high mannose and complex 
glycans. Individual N-glycosylation site mutants S269A, T280A, S441A, 
T553A were constructed, and results indicated that all sites were occupied. 
T280A was found to accumulate in the endoplasmic reticulum as the non-
processed precursor of the enzyme. Furthermore, it exhibited only residual 
levels of metalloprotease activity in vivo towards the L1 cell adhesion 
molecule, as well as in vitro, using a proTNF-alpha peptide as substrate. 
S441A showed increased ADAM10 susceptibility to proteolysis. Mutation of 
N267, N439, and N551 did not completely abolish enzyme activity, 
however, reduced levels were found.  
ADAM10 is sorted into secretory vesicles, the exosomes. Here, a 
fraction of ADAM10 from exosomes was found to contain more processed 
N-linked glycans than the cellular enzyme. 
In conclusion, N-glycosylation is crucial for ADAM10 processing and 
resistance to proteolysis, and results suggest that it is required for full-
enzyme activity. 
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2.2. Introduction 
 
ADAM (a disintegrin and metalloprotease) 10 is a type I 
transmembrane glycoprotein that belongs to the ADAMs protein family. It is 
characterized by a conserved domain structure, consisting of an N-terminal 
signal sequence that directs the protein to the secretory pathway followed 
by a prodomain, a metalloprotease, a disintegrin domain, a cystein-rich 
region, a transmembrane domain, and an SH3- enriched cytoplasmic tail 
(Wolfsberg et al., 1995). In order to be catalytically active ADAM10 
prodomain has to be cleaved by proprotein convertases furin and/or PC7 in 
the Golgi compartments (Anders et al., 2001; Schlondorff and Blobel, 1999; 
Seals and Courtneidge, 2003).  
ADAM10 metalloprotease domain is known to mediate the 
proteolytic cleavage of transmembrane proteins in their juxtamembrane 
region resulting in the release of the extracellular domain as a soluble form 
(shedding). ADAM10 can cleave a variety of proteins with importance in 
development, cell signalling and disease, such as the cell adhesion 
molecule L1 (Mechtersheimer et al., 2001), pro-tumour necrosis factor-
alpha (Lunn et al., 1997), type IV collagen (Millichip et al., 1998), amyloid 
precursor protein (Lammich et al., 1999), ephrin-A2 (Hattori et al., 2000), 
epidermal growth factor receptor (Yan et al., 2002), notch (Dallas et al., 
1999; Hartmann et al., 2002), pro-heparin-binding epidermal growth factor 
(Lemjabbar and Basbaum, 2002), fractalkine (Hundhausen et al., 2003), 
CD44 (Nagano et al., 2004), N-cadherin (Reiss et al.; 2005), betacellulin 
(Sanderson et al., 2005), and low-affinity immunoglobulin E receptor CD23 
(Weskamp et al., 2006), among others. Moreover, ADAM10 is 
overexpressed in tumours, such as uterine and ovarian carcinomas (Fogel 
et al., 2003), human haematological malignancies (Wu et al., 1997), 
neuroblastomas (Yavari et al., 1998), prostate cancer (McCulloch et al., 
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2004), gastric carcinoma cells (Tanida et al., 2007), colon cancers (Gavert 
et al., 2005), and oral squamous cell carcinoma (Ko et al., 2007), 
suggesting a role in tumour progression and dissemination. 
ADAMs disintegrin and cystein-rich domains were described as 
being directly involved in cell-cell adhesion processes through interactions 
with integrins and other receptors (White, 2003). 
ADAM10 can be found in various cellular compartments. It has been 
shown to colocalize with Golgi markers and was found on the cell surface 
(Lammich et al., 1999; Gutwein et al., 2003). More recently, it was also 
detected in secreted vesicles identified as exosomes (Gutwein et al., 2003). 
Exosomes are small membrane vesicles (30-100 nm diameter) secreted by 
various cell types as a consequence of fusion of multivesicular late 
endosomes/lysosomes with the plasma membrane. Exosomes secretion 
has first been reported in a variety of cells, including cancer cells, neurons, 
B lymphocytes, T lymphocytes, dendritic cells, mast cells, and platelets 
(Caby et al., 2005). Exosomes secreted from tumour cells could promote 
cellular invasion and migration during metastasis (Stoeck et al., 2006). 
ADAM10, like other ADAMs, is N-glycosylated. It has four potential 
N-glycosylation sites (N-X-S/T, X≠Pro), three located in the metalloprotease 
domain (N267, N278, and N439) and one in the disintegrin domain (N551). 
Glycosylation is one of the most important post-translational modifications 
in newly synthesized proteins which may influence the physicochemical 
and biological properties of glycoproteins. N-glycosylation has been related 
with protein folding and quality control of glycoproteins in the endoplasmic 
reticulum with consequences for processing and trafficking (reviewed in 
Helenius and Aebi, 2004; Morais et al., 2003), targeting in the secretory 
pathway, namely to the lysosome (via the mannose 6-phosphate receptor) 
(Hauri et al., 2000), dynamics of plasma membrane proteins (Cai et al., 
2005; Brooks et al., 2006; Turner et al., 2006), cell-cell interactions, e.g., 
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during metastases formation (Dube et al., 2005), or inflammation (Dube et 
al., 2005; Lowe et al., 2003), among others. 
In cancer, aberrant glycosylation, particularly of cell surface 
glycoconjugates, is a hallmark associated with the disease (Dube et al., 
2005). Altered glycosylation is the consequence of changes in 
glycosyltransferase expression and localization along the secretory 
pathway and also depends on the availability of sugar nucleotide donors in 
the Golgi lumen. 
In the present work, the four potential N-glycosylation sites of 
bADAM10 were found to be occupied. By mutating each of those sites we 
observed that glycans from N278 were crucial for the intracellular 
processing of bADAM10, with the enzyme being accumulated as the 
precursor in the endoplasmic reticulum. Concerning N439, the N-glycans 
protected against proteolytic cleavage. N-glycans from each mutant were 
required for full in vivo activity. On the other hand, a fraction of human 
endogenous ADAM10 from exosomes was found to contain more 
processed N-linked glycans than the cellular counterpart. 
 
 
2.3. Materials and methods 
 
2.3.1. DNA constructs 
 
The plasmid pcDNA3-ADAM10wt (Mechtersheimer et al., 2001) 
coding for wild-type bovine ADAM10 with the HA tag at the C-terminus was 
used as template for the construction of the N-glycosylation mutants: 
pbADAM10S269A, pbADAM10T280A, pbADAM10S441A, and 
pbADAM10T553A. Site-directed mutagenesis was done using 
 Functional role of ADAM10 N-glycosylation 
 
35 
QuickChange cloning techniques (Stratagene, La Jolla, CA, USA), following 
the manufacturer's instructions. The serine or threonine from the N-
glycosylation site (N-X-S/T) were replaced by an alanine residue following a 
strategy previously used (Morais et al., 2003; Morais et al., 2006). 
The PCR reactions were carried out with 50-115 ng pcDNA3-
ADAM10wt as template, 2.5 mM dNTPs mix, 2.5 U/µl Pfu Turbo DNA 
Polymerase and 10 µM of mutagenic primers. The primers used to obtain 
pbADAM10S269A, pbADAM10T280A, pbADAM10S441A, and 
pbADAM10T553A were, respectively as follows: 5′GGA ATT CGT AAC ATC 
GCT TTC ATG GTG AAA CGC ATA AG3′, 5′GC ATA AGA ATC AAC ACA 
GCT GCT GAT GAG AAG G3′, 5′GT AGT ATT AGA AAT ATA GCT CAA 
GTT CTT GAG AAG AAG3′, 5′GAT CCT AAA CCG AAC TTC GCA GAC 
TGT AAT AGA CAT ACG3′. Standard molecular biology techniques were 
used for PCR product restriction and analysis. Mutations of the bADAM10 
N-glycosylation sites were confirmed by automatic DNA sequencing 
analysis. 
 
2.3.2. Cell culture and protein expression 
 
Human ovarian cancer SKOV3 cells, human embryonic kidney 
HEK293 cells and mouse embryonic fibroblasts (MEFs) were grown at 37 
°C, 5% CO2 in Dulbecco's Modified Eagle Medium (DMEM) (Sigma) 
supplemented with 10% fetal calf serum (Gibco), 1% penicillin/streptomycin 
solution (Gibco). 
SKOV3 and HEK293 were transfected with each of the plasmids 
indicated in 2.3.1 or pcDNA3-L1 by the calcium phosphate technique using 
5 µg of plasmid DNA and selection of stably-transfected cells was 
performed using 2 and 1 mg/ml geneticin sulphate G-418 (Gibco), 
respectively. For transient expression, HEK293 cells and MEFs were 
Chapter 2 
36 
transfected with 2 or 2.5 µg of plasmid DNA, respectively, using 
Lipofectamine 2000 (Invitrogen), following manufacturer's instructions. 
 
2.3.3. Isolation of membrane vesicles 
 
Confluent SKOV3 cells were cultivated for 24 h in serum-free 
medium. When indicated, cells were incubated with 10 µM TAPI-0 
(Calbiochem) for 16 h. Supernatant was collected and centrifuged, at 4 °C, 
for 10 min, at 500 × g followed by 20 min at 10,000 × g to remove dead 
cells and cell debris, respectively. Membrane vesicles were collected by 
centrifugation at 100,000 × g, for 2 h, at 4 °C. 
For sucrose-density fractionation, membrane vesicles resuspended 
in 0.25 M sucrose were loaded on the top of a step gradient comprising 
different sucrose concentrations: 2, 1.3, 1.16, 0.8, 0.5, and 0.25 M as 
previously described (Stoeck et al., 2006). The gradients were centrifuged 
at 100,000 × g for 2.5 h. Twelve 1 ml fractions were collected from the top 
of the gradient and precipitated with chloroform/methanol (1:4, v/v). 
Samples were solubilized in sample buffer with or without β-
mercaptoethanol for SDS-PAGE and Western blot analysis. 
 
2.3.4. In vivo cleavage assay 
 
HEK293 cells were stably-transfected with pcDNA3-L1 (HEK-L1), 
and the selected stable cell lines were then transiently-transfected with 
pcDNA3-ADAM10wt or one of the N-glycosylation mutants. MEFs were 
transiently-double transfected with pcDNA3-L1 and pcDNA3.1-LacZ, 
pcDNA3-ADAM10wt, or one of the N-glycosylation mutants. Forty-eight 
hours after transfection, supernatant corresponding to a 24 h-production in 
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serum-depleted medium, was centrifuged at 500 x g, 10 min and 10.000 x 
g, 20 min. When indicated, MEFs were incubated with the ADAM17 
inhibitor Bristol Meyer Squib (BMS) (kindly provided by Dr. J. Arribas) for 24 
h in serum-depleted medium. Cell supernatant was analysed by Western 
blot. 
 
2.3.5. SDS-PAGE and Western blot analysis 
 
Total protein lysates were obtained by solubilization of centrifuged 
cells in RIPA buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% SDS, 1% 
sodium deoxycholate, 1% Triton X-100, 1:50 complete protease inhibitors 
cocktail (Roche), for 10 min. Protein was precipitated with ethanol and 
solubilized in reducing SDS-PAGE sample buffer. Endogenous hADAM10 
analysis was performed in non-reducing SDS-PAGE. For SDS-PAGE 7.5% 
acrylamide gels or pre-casted 4-12% acrylamide Bis-Tris gels (Invitrogen) 
were used. Western blot was performed using the following primary 
antibodies: rabbit anti-ADAM10 antibody AB387 (1:1000) raised against 
amino acids 732-748 of ADAM10 of human origin produced and purified by 
Davids Biotechnologies, mouse anti-ADAM10 monoclonal antibody 
MAB1427 (1:1000) (R&D), mouse anti-HA tag 6E2 monoclonal antibody 
(1:1000) (Cell Signalling), mouse anti-L1 11A (1:3), mouse antihuman CD9 
(1:5000), mouse anti-annexin I monoclonal antibody (1:5000) (BD 
Biosciences), and mouse anti-ubiquitin P4D1 monoclonal antibody (1:1000) 
(Santa Cruz Biotechnology). Secondary antibodies were sheep anti-mouse 
IgG coupled to HRP (1:4000) or donkey anti-rabbit IgG coupled to HRP 
(Amersham) (1:3000). Antibody detection was accomplished with ECL Plus 
Western Blotting Detection Reagent (GE Healthcare). 
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2.3.6. Protein deglycosylation 
 
For glycosidase hydrolysis cell lysates (approximately 1x106 cells) 
were incubated with endoglycosidase H (Endo H) (New England Biolabs) 
and peptide: N-glycosidase F (PNGase F) (New England Biolabs or 
Roche), according to supplier's protocol. Briefly, cell lysates were 
denatured in glycoprotein denaturing buffer (0.5% SDS with or without 1% 
β-mercaptoethanol) at 100 °C for 10 min, and incubated with 
deglycosylation enzyme (PNGase F or Endo H) in the corresponding buffer. 
Hydrolysis was carried out at 37 °C for 3 h or overnight. The samples were 
further analyzed by SDS-PAGE and Western blot. 
 
2.3.7. Immunoprecipitation 
 
Exosomes were lysed with BOG buffer (20 mM Tris-HCl pH 8.0, 50 
mM β-octylglucopyranoside (BOG), 1 mM phenylmethylsulphonylfluoride 
(PMSF), 10 mM sodium fluoride, 10 mM sodium orthovanadate, 1:50 
complete protease inhibitors cocktail (Roche) for 30 min at 4 °C with 
occasional vortexing. 
Pre-cleared lysates were incubated for 1 h at 4 °C with a rabbit anti-
HA.11 polyclonal antibody (Covance) previously coupled to protein A/G 
Plus agarose beads (Santa Cruz Biotechnologies). Immunoprecipitated 
proteins were washed three times with BOG buffer and were eluted at 100 
°C for 5 min with sample buffer. Samples were analysed by SDS-PAGE 
and Western blot. 
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2.3.8. Confocal immunofluorescence microscopy 
 
Cells were grown on glass coverslips until they reached 80% 
confluence, they were washed with PBS containing 0.5 mM MgCl2, fixed 
with 4% paraformaldehyde and permeabilized with methanol/acetone (1:1) 
solution for 10 min at -20 °C. Blocking was done with 1% BSA in PBS for 1 
h and primary and secondary antibodies were incubated at room 
temperature for 2 and 1 h, respectively. Antibody solutions were prepared 
in blocking solution and washes were performed with PBS. Coverslips were 
mounted in Airvol and examined on a Leica Confocal (SP2+AOBS) 
microscope. Primary antibodies were: rabbit anti-HA.11 (1:1000) 
(Covance), goat IgG anti-calnexin C-20 (1:500) (Santa Cruz), mouse IgG 
anti-ERGIC53 (1:1000) (Alexis Biochemicals), mouse IgG anti-GM130 
(1:200) (BD Biosciences), mouse IgG anti-EEA1 (1:100) (BD Biosciences), 
and mouse IgG anti-LAMP1 H4A3 (1:100) (BD Biosciences). 
Secondary antibodies were: donkey anti-rabbit IgG AlexaFluor 594 
(1:500), donkey anti-goat IgG AlexaFluor 488 (1:500), and donkey anti-
mouse IgG AlexaFluor 488 (1:500) (Molecular Probes). 
For each picture, laser intensities and amplifier gains were adjusted 
in order to avoid pixel saturation. Each fluorophore used was excited 
independently and sequential detection was performed. Each picture 
consisted of a z-series of 20 images of 1024-1024 pixel resolution with a 
pinhole of 1.0 airy unit. Colocalization analysis was performed using the 
open source Image J version 1.37 (http://rsb.info.nih.gov/ij/). 
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2.3.9. Peptide cleavage assay 
 
ADAM10-HA immunoprecipitates in 90 µl were incubated with 10 µl 
(final concentration 50 mM) fluorescent quenching peptide Abz-Leu-Ala-
Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Dap(dnp)-NH2 (Peptide International, 
Louisville, Kentucky, USA). Cleavage was followed in a fluorescent plate 
reader (Fluoroskan Ascent FL Thermo-Electron Corporation) using filters 
for excitation at 320 nm and emission at 405 nm. 
 
2.3.10. ADAM10 structure 
 
Comparative modelling methods (Sali et al., 1993) were used to 
derive the structure of the metalloprotease domain of bovine ADAM10 on 
basis of the same domain from human ADAM17, the closest homologue 
with three-dimensional structure determined (Maskos et al., 1998) (PDB 
code 1BKC). These two domains have 39% identity, which should be 
enough for deriving a model for ADAM10 with reasonable quality (Sanchez 
et al., 1997). 
The program MODELLER (Sali et al., 1993) version 7.7 was used in 
the comparative modelling procedures. Resulting structures were analysed 
with PROCHECK (Laskowski et al., 1993). A large number of models were 
calculated, and the one having the lowest value of the objective function 
was selected. Problems on the alignment were corrected and new models 
were calculated in an iterative manner. A Ramachandran plot analysis of 
the final model showed it to have 87.0% residues in most favored regions, 
12.5% in additional allowed regions and 0.5% (1 residue) in disallowed 
regions. This residue is Cys 344, which is involved in a disulphide bridge 
with Cys 451, and corresponds to a cystein residue in the ADAM17 
 Functional role of ADAM10 N-glycosylation 
 
41 
template (Cys 365) that is also located in a disallowed zone of the 
Ramachandran plot. 
 
 
2.4. Results 
 
2.4.1. The N-glycosylation sites of hADAM10 are occupied 
 
ADAM10 contains four potential N-glycosylation sites in the mature 
form of the protein (Figure 5). Three of these sites are located in the 
metalloprotease domain: N267, N278 and N439 and one in the disintegrin 
domain: N551. Endogenous human ADAM10 from SKOV3 ovarian 
carcinoma cells appeared as a major band with an apparent molecular 
mass of approximately 68 kDa (Figure 6, A). By enzymatic digestion with 
Endo H, that removes N-linked glycans of the high mannose and hybrid 
type, we observed that the hADAM10 mature form underwent a downward 
shift of approximately 5 kDa. On the other hand, hydrolysis with PNGase F, 
that removes both high mannose, hybrid, and complex type N-linked 
glycans, reduced the molecular mass by 9 kDa to the expected value for 
the hADAM10 core protein without the prodomain and with no post-
translational modifications (59 kDa) (Figure 6, A). These results indicated 
that ADAM10 contained high mannose as well as complex N-glycans.  
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Figure 5. Schematic representation of ADAM10 and N-glycosylation mutants. 
Signal peptide-Pre; prodomain-Pro; metalloprotease domain-MP; disintegrin 
domain-Disintegrin; cystein-rich region-Cys-rich; transmembrane region-TM and 
cytoplasmic tail-Cyt. The four potential N-glycosylation sites (Y) are located in the 
MP (N267, N278, and N439), and in the disintegrin domain (N551). ADAM10 N-
glycosylation mutants were created by mutating the Ser or Thr residues from the N-
glycosylation sites (N-X-S/T) to Ala residues. 
 
 
To investigate the functional role played by the N-linked glycans, 
each potential N-glycosylation site was mutated. We used HA-tagged 
bovine ADAM10, which shares high homology with human ADAM10 protein 
sequence (97%), since several attempts to mutate the N-glycosylation sites 
of hADAM10 were not successful. Serine or threonine residues of each 
bADAM10 N-glycosylation site (N-X-T/S) were replaced by alanine, 
creating four bADAM10 N-glycosylation mutants: S269A, T280A, S441A, 
and T553A (Figure 5). 
SKOV3 ovarian cancer cells were stably-transfected with the 
pcDNA3 vector coding for bADAM10wt or S269A, T280A, S441A, and 
T553A mutants. Stable cell lines were established and recombinant protein 
expression was analysed by SDS-PAGE and Western blot, using a mouse 
anti-HA tag antibody (Figure 6, B). All mutants were detected at lower 
molecular masses than the wild-type form, which indicated that all N-
glycosylation sites were occupied. Most striking was the observation that 
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mutant T280A accumulated as the precursor format approximately 100 
kDa, the mature form being detected at very low levels, which indicated that 
N-linked glycans from N278 were required for bADAM10 processing. 
Mutant S441A underwent proteolysis with an abundant cleavage product at 
52 kDa. Therefore, the N-linked glycans from N439 protected bADAM10 
from proteolysis. The highest shift was observed for T553A, which 
suggested that this site contained complex glycans, whereas the others 
contained high mannose glycans. 
To investigate the type of glycans present in each N-glycosylation 
site, Endo H and PNGase F digestion of bADAM10wt and mutants was 
performed (Figure 6, C). Forms containing only high mannose glycans 
exhibited similar shifts in SDS-PAGE after deglycosylation with each of the 
enzymes, whereas forms containing high mannose and complex glycans 
exhibited higher shifts after PNGase F than after Endo H deglycosylation. 
In view of this, it was concluded that the mature form of bADAM10wt 
contained high mannose and complex glycans similarly to endogenous 
hADAM10. The precursor form of bADAM10wt contained high mannose 
and complex glycans, which indicated that it was transported beyond the 
ER to the Golgi, where it is known to be processed. On the other hand, 
precursor T280A contained only high mannose glycans suggesting that it 
probably accumulated in the ER. Mature S441A and T553A only contained 
high mannose N-glycans, which suggested that either N439 or N551 could 
contain complex N-glycans. 
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Figure 6.  Western blot analysis of ADAM10 and N-glycosylation mutants 
from SKOV3 cells. (A) Deglycosylation of endogenous hADAM10 (1x10
6
 
cells/lane) with Endo H and PNGase F. Analysis was performed under non-
reducing conditions using a mouse anti-ADAM10 antibody MAB1427. (B) Analysis 
of cells stably transfected with either bADAM10wt or N-glycosylation mutants under 
reducing conditions using a mouse anti-HA tag antibody. (C) Deglycosylation of 
bADAM10wt and bADAM10 N-glycosylation mutants with Endo H and PNGase F. 
Precursor (p) or mature (m) ADAM10 are indicated with closed arrowheads. 
Corresponding deglycosylated bands are shown with open arrowheads and the 
asterisk indicates bADAM10 cleavage product. 
 
 
2.4.2. Intracellular localization of bADAM10 N-glycosylation 
mutants 
 
In agreement with previous reports (Dallas et al., 1999; Reiss et al., 
2005), the analysis of the localization of endogenous hADAM10 by confocal 
microscopy of SKOV3 ovarian carcinoma cells showed predominant 
localization of the protein at the perinuclear region and at the cell surface 
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where it appeared as punctuated dots evenly distributed at the plasma 
membrane (results not shown). 
Since it has been reported that removal of N-glycosylation sites from 
proteins can affect protein transport and intracellular localization (Martina et 
al., 1998), bADAM10wt and mutants were colocalized with markers of the 
secretory pathway using confocal immunofluorescence microscopy. The 
markers used were: endoplasmic reticulum (ER) - calnexin, ER - Golgi 
intermediate compartment (ERGIC) - ERGIC53, Golgi - GM130, early 
endosomal antigen-1 - EEA1, and late endosome/lysosome-associated 
membrane protein 1 - LAMP1 (Figure 7).  
Bovine ADAM10wt colocalized with the EEA1 marker (Figure 7, D), 
which indicated that it was present in the endosomes. Low levels of protein 
were also found to colocalize with calnexin (Figure 7, A), and to a lower 
extent with GM130 (Figure 7, C) and ERGIC53 (Figure 7, B), probably 
corresponding to protein in traffick through the ER, Golgi and ERGIC. No 
colocalization with LAMP1 was observed (Figure 7, E). All mutants, with the 
exception of T280A, showed a similar staining profile (results not shown). 
T280A mutant showed higher colocalization with calnexin (Figure 7, F). 
These results showed that this mutant was retained in the ER and agreed 
with T280A precursor accumulation and its sensitivity to both Endo H and 
PNGase F. 
Moreover, membrane protein biotinylation confirmed that most 
mature hADAM10 and bADAM10wt mature forms were localized at the 
plasma membrane. All N-glycosylation mutants showed comparable 
expression levels, at the cell surface, compared with bADAM10wt, with the 
exception of T280A that was almost undetectable (results not shown). 
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Figure 7. Colocalization of bADAM10wt and T280A mutant, with markers of 
the secretory pathway by confocal immunofluorescence microscopy. SKOV3 
cells stably-transfected with bADAM10wt (red) were fixed in 1:1 methanol/acetone 
and double labelled with rabbit anti-HA tag antibody and one of the following 
markers (green): (A) goat anti-calnexin; (B) mouse anti-ERGIC53; (C) mouse anti-
GM130; (D) mouse anti-EEA1 or (E) mouse anti-LAMP1. (F) T280A mutant (red) 
was double labelled with rabbit anti-HA tag antibody and goat anti-calnexin (green). 
Secondary antibodies were donkey anti-rabbit IgG AlexaFluor 594, donkey anti-
mouse IgG AlexaFluor 488 and donkey anti-goat IgG AlexaFluor 488. Scale bars, 
10 µm. 
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2.4.3. In vivo and in vitro activity of bADAM10wt and N-
glycosylation mutants 
 
The shedding activity of bADAM10wt and glycosylation mutants 
towards the L1 cell adhesion molecule was investigated. L1 is a 220 kDa 
type I membrane glycoprotein of the immunoglobulin family that is 
overexpressed in many human tumour cell lines, such as neuroblastomas, 
melanomas (Fogel et al., 2003), colon (Gavert et al., 2005), and ovarian 
carcinomas (Fogel et al., 2003), as well as in neural, hematopoietic, and 
certain epithelial cells. L1 cleavage by ADAM10 occurs in intracellular 
compartments, predominantly at the plasma membrane, and exosomes, 
and results in two distinct fragments: a fragment of approximately 32 kDa 
that remains attached to the cell membrane and a soluble fragment of 
approximately 200 kDa that is released and can be detected in the 
supernatant. 
HEK293 cells were selected for this study since they show low 
expression levels of endogenous hADAM10 and L1, and almost no L1 
shedding (Figure 8, Ctr). Therefore, HEK293 cells were stably transfected 
with pcDNA3-L1 (HEK-L1), and the selected stable cell lines were then 
transiently transfected with bADAM10wt and glycosylation mutants. Forty 
eight hours after transfection, L1 from the cell supernatants corresponding 
to a 24 h-production in serum depleted medium, was analyzed by Western 
blot and a representative blot is shown (Figure 8, upper panel). As controls 
L1 and bADAM10 from the corresponding cell extracts were also analyzed 
by Western blot. Mature full-length L1 probably at the plasma membrane 
was detected (Figure 8, middle panel). Bovine ADAM10wt and mutants 
were detected as mature form and precursor (Figure 8, lower panel). 
Mutant T280A exhibited very low levels of mature form. 
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Transient overexpression of bADAM10wt in cells stably-
overexpressing L1 led to the detection of a higher level of shed L1 to the 
supernatant (Figure 8). Mutation of N278 caused a decrease in the amount 
of shed L1 to almost undetectable levels. Transfection with the other 
mutants did not completely abolish the production of soluble L1, however, 
the levels appeared to decrease. 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. L1 cleavage by bADAM10wt and N-glycosylation mutants in HEK293 
cells. HEK293-L1 cells were co-transfected with bADAM10wt or each of the N-
glycosylation mutants. Cell supernatants were analyzed by Western blot using a 
mouse anti-L1 11A antibody to detect cleaved L1. Results shown are from a 
representative blot from two independent experiments done in duplicate. Controls 
for corresponding full-length L1 and bADAM10 are shown in middle and lower 
panels, respectively. 
 
 
The effect of ADAM10 N-glycosylation mutations in L1 protein 
cleavage, in vivo, was also investigated in primary mouse embryonic 
fibroblasts knockout for ADAM10 (ADAM10-/- MEFs) (Hartmann et al., 
2002). These cells are Simian virus large T antigen (SV-T)-immortalized 
and derive from ADAM10-deficient mice. As a positive control we used 
ADAM10+/+ MEFs that express endogenous ADAM10 (Figure 9, A). 
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MEFs were transiently-double transfected with pcDNA3-L1 and the 
empty vector pcNA3.1-LacZ, bADAM10wt, or one of the N-glycosylation 
mutants. Forty-eight hours after transfection, the supernatant 
corresponding to a 24 h-production in serum-depleted medium, was 
collected and analysed by Western blot (Figure 9, B). As controls L1 and 
bADAM10 from the corresponding cell extracts were also analyzed by 
Western blot (Figure 9, B). 
 
 
Figure 9. L1 cleavage in ADAM10
-/-
 MEFs transiently overexpressing pcDNA3-
L1 and pcDNA3.1-LacZ, bADAM10wt or each of the N-glycosylation mutants. 
(A) Analysis of endogenous mADAM10 protein in ADAM10
-/-
 and ADAM10
+/+
 MEFs 
using the polyclonal antibody rabbit anti mouse ADAM10 AB387. (B) L1 cleavage 
in MEFs in the absence or presence of 5 µM of the ADAM17 inhibitor, BMS. MEFs 
supernatants were analyzed by Western blot using a mouse anti-L1 11A antibody 
to detect cleaved L1. Controls for corresponding full-length L1 and bADAM10 are 
shown in middle and lower panels, respectively. 
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Although, L1 cleavage levels in ADAM10-/- MEFs were lower than in 
ADAM10+/+ MEFs, the production of soluble L1 was not completely 
abolished (Figure 9, B). It has been described that in wt MEFs two ADAM 
protein family members can cleave L1: while ADAM10 cleaves L1 
constitutively, ADAM17 needs to be induced by phorbol-12-myristate-13-
acetate (PMA) or methyl-β-cyclodextrin (MCD) (Maretzy et al., 2005). 
Nevertheless, it is possible that in absence of ADAM10, ADAM17 can 
compensate and contribute to the constitutive L1 cleavage. 
Since there was still cleavage of L1 in ADAM10-/- MEFs, that could 
possibly be attributed to ADAM17 (Gutwein et al., 2005; Maretzky et al., 
2005), L1 cleavage assay was done in the presence of 5 µM ADAM17 
inhibitor - BMS. After incubation with BMS a decrease in L1 cleavage levels 
was observed both for ADAM10-/- and ADAM10+/+ MEFS. In addition, in 
agreement with the results obtained above using HEK293 cells (Figure 8), 
mutation of N278 caused a decrease in the amount of shed L1 (Figure 9, 
B).  
Since the in vivo activity is influenced by the catalytic activity of 
ADAM10 as well as its intracellular localization, we determined the 
proteolytic activity using a cell-free assay for mutants T280A and S269A 
that had the highest and the lowest alterations of in vivo activity, 
respectively. HEK293 cells were transiently doubly-transfected with 
bADAM10wt or with S269A and T280A mutants solubilized in lysis buffer 
and subjected to immunoprecipitation with anti-HA antibody to isolate the 
proteins. After washing, the precipitated proteins were incubated with the 
fluorescent quenching peptide Abz-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-
Arg-Dap(dnp)-NH2 containing the ADAM cleavage site of TNF-alpha. 
Bovine ADAM10wt and glycosylation mutant forms were efficiently 
purified from cell lysates of HEK293 cells and were able to cleave the TNF-
alpha peptide in a time dependent fashion. A reduced cleavage of the 
peptide to approximately 60% of the value obtained for bADAM10wt was 
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found for S269A (Figure 10). On the other hand, a reduction to 28% was 
observed for the T280A mutant, which could be due to an inactivating effect 
or to the lower level of mature form. Due to double transient transfection, 
high levels of precursor were detected, which most likely did not contribute 
to cleavage since to this date no proteolytic activity has been described for 
the precursor form, and only minor amounts of mature ADAM10 were 
detected. Similar results were obtained when the proteins were expressed 
in SKOV3 cells (data not shown). In transient transfections ADAM17 also 
accumulates as the pro-form in the early secretory pathway, while little or 
no processed form can be detected (reviewed in Arribas et al, 2005). These 
results corroborated the findings of the in vivo L1 cleavage assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Measurement of the proteolytic activity of bADAM10wt and S269A, 
T280A N-glycosylation mutants using a fluorescent TNF-alpha peptide 
cleavage assay. The analysis was carried out in triplicate. Data are represented 
as mean values ± SD. Transfection efficiency was monitored by Western blot using 
a mouse anti-HA tag antibody (lower panel). Precursor (p) or mature (m) bADAM10 
are indicated with closed arrowheads. 
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2.4.4. Characterization of ADAM10 from exosomes 
 
ADAM10 has been found in exosomes, where it promotes the 
shedding of several substrates, such as L1 and CD44 (Gutwein et al., 
2003; Stoeck et al., 2006). To investigate if glycosylation would play a role 
in glycoprotein sorting to exosomes, endogenous hADAM10 from cell 
extracts and exosomes was analysed by SDS-PAGE and Western blot, and 
further digested with Endo H and PNGase F (Figure 11 A, B). 
Exosomes were collected in the pellet after ultracentrifugation of 
cleared supernatants from SKOV3 cells followed by sucrose-density 
fractionation as previously described (Stoeck et al., 2006). Since hADAM10 
was only detected in fractions that are positive for the exosomal marker 
CD9 (Figure 11, A), the remaining studies were performed using exosomes 
obtained after ultracentrifugation without further fractionation. 
Endogenous human ADAM10 from the exosomes appeared as a 
double band, the lighter one co-migrating with that from the cell extract (see 
Figure 11, A). The heavier band was resistant to digestion with Endo H but 
sensitive to PNGase F whereas the lighter band was sensitive to both Endo 
H and PNGase F (Figure 11, B). The products of digestion with PNGase F 
also resulted in a double band. These results suggested that the heavier 
band contained complex glycans, whereas the lighter band contained both 
high mannose and complex glycans similarly to hADAM10 from the cell 
extract. The presence of two bands after PNGase F digestion indicated an 
additional post-translational modification for the heavier band or proteolytic 
degradation.  
On the other hand, a proteolytic product of hADAM10 was detected 
in exosomes but not in the cellular extract. Further experiments showed 
that such proteolysis was catalyzed by a metalloprotease since it was 
prevented when the cells were incubated with TAPI-0, a metalloprotease 
inhibitor (Mohler et al., 1994) (Figure 11, C, upper panel). As control for the 
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presence of exosomes the same blot was probed with anti-annexin I, an 
exosomal marker (Figure 11, C, lower panel). 
 
 
Figure 11. Western blot analysis of endogenous hADAM10 from SKOV3 cell 
extracts and exosomes. (A) Total protein from cell extracts (Ext; 1x10
6
 cells/lane), 
exosomes (Exo; 1.5x10
7
 cells), and exosomes fractionated by centrifugation in 
sucrose gradient, were analysed under non-reducing conditions using the mouse 
anti-ADAM10 antibody MAB1427. Exosomal marker CD9 was detected as a 
control using a different concentration gel. (B) Deglycosylation of hADAM10, from 
exosomes obtained after ultracentrifugation, with Endo H and PNGase F. (C) 
Exosomes were incubated for 16 h with the metalloprotease inhibitor TAPI-0. 
Annexin I, an exosomal marker was detected as an input control. Precursor (p) or 
mature (m) ADAM10 are indicated with closed arrowheads. Corresponding 
deglycosylated bands are shown with open arrowheads and asterisk indicates 
ADAM10 cleavage product. 
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For comparison, recombinant bADAM10wt and mutants 
overexpressed in SKOV3 cells were analysed (Figure 12, A). Precursor 
T280A was not found in the exosomes, which is in agreement with the 
previous results indicating that it is retained in the ER. Mature forms of 
bADAM10wt, S269A, S441A, and T553A were found in the exosomes, 
however, they were not detected as a double band, contrary to endogenous 
hADAM10, probably due to the low levels of bADAM10 expression. In 
addition, they all migrated at a slightly higher molecular mass than their 
cellular counterparts. The increased mass estimation could be due to post-
translational modifications, such as N-glycosylation or ubiquitination. 
Immunoprecipitation of bADAM10wt followed by Western blot analysis 
using an anti-ubiquitin antibody allowed the identification of three bands 
(Figure 12, B). The heavier band co-migrated with the mature form of 
bADAM10wt, therefore suggesting that it was ubiquitinated. The other two 
bands possibly corresponded to other ubiquitinated proteins that may 
interact with bADAM10wt. As controls total cellular and exosomal proteins 
were also analysed (Figure 12, B). Exosomal proteins were heavily 
ubiquitinated in comparison with cellular proteins. High proteolytic activity 
from the exosomes hindered PNGase F digestion analysis.  
Proteolytic cleavage also occurred for exosomal bADAM10wt and 
mutants similarly to endogenous hADAM10. This cleavage was particularly 
evident for mutant S441A. These results further support the importance of 
the N-linked glycans from N439 to protect the protein against proteolysis. 
Deglycosylation of exosomal bADAM10 remained inconclusive due to high 
level of protein degradation. 
Detection of CD9, an exosomal marker, revealed no differences in 
the amount of secreted vesicles produced in all the four N-glycosylation 
mutants when compared with the bADAM10wt (results not shown). 
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Figure 12. Western blot analysis of bADAM10wt and N-glycosylation mutants 
from stably transfected SKOV3 cells. (A) Total protein from cell extracts (Ext; 
1x10
6
 cells/lane) and exosomes (Exo; 1.5x10
7
 cells) were analysed using a mouse 
anti-HA tag antibody. Precursor (p) or mature (m) bADAM10 are indicated with 
closed arrowheads and asterisk indicates bADAM10 cleavage product. (B) Protein 
ubiquitination of cell extract (100 µg total protein), corresponding exosomes (70 µg 
total protein) and immunoprecipitated exosomal bADAM10wt. Analysis was 
performed using mouse anti-Ubiquitin P4D1 (Ub) and mouse anti-HA tag 
antibodies (HA). Mature (m) bADAM10 is indicated with closed arrowhead and 
asterisk indicates ubiquitinated proteins that interact with bADAM10. 
 
 
2.4.5. Modelling of the 3D structure of bADAM10 
metalloprotease domain 
 
A model of bADAM10 metalloprotease domain based on its 
homology with ADAM17 (39% identity) was constructed to investigate the 
structural basis for the decreased in vitro activity of S269A, the absence of 
T280A processing and the susceptibility of S441A to proteolytic 
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degradation, as well as significantly decreased in vivo activities of T280A 
and S441A (Figure 13). Both N267 and N278 glycosylation sites are 
located in exposed zones before and after beta-strands, respectively, in 
loop regions as expected. The N267 residue has one glycosylation 
counterpart in ADAM17 (N264) in a spatially related region (not sequence 
related). The N278 has no counterpart on ADAM17. Surprisingly, the N439 
glycosylation site is located inside an alpha-helix. In a related spatial zone 
in ADAM17, there is potential glycosylation site N452, which is, however, 
located at the beginning of the helix and not inside it as in the case of 
ADAM10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Representation of the three-dimensional model for bADAM10 
metalloprotease domain, rendered using cartoons. The potential N-
glycosylation residues are highlighted using CPK models and labelled. Figure 
produced using PyMol (DeLano, Palo Alto, 2002). 
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2.5. Discussion 
 
Glycosylation is an important post-translational modification that 
plays an important role in a number of physiological and biochemical 
properties of a glycoprotein including stability, folding, intracellular 
trafficking, or activity (Helenius et al., 2003). However, N-linked 
glycosylation does not occur at every potential site and the role played by 
glycosylation in different proteins is highly variable and depends on the 
individual protein. 
ADAM10 is a glycoprotein with four potential N-glycosylation sites: 
N267, N278, N439, and N551 but the functional role of ADAM10 N-
glycosylation is unknown. To investigate if N-glycosylation has any role on 
ADAM10 processing, stability, activity, and intracellular localization, the four 
potential sites were mutated and characterized individually. 
Our results showed that all four bADAM10 N-glycosylation sites 
were occupied with high mannose or complex glycans. Moreover, the 
mutation of a single N-glycosylation consensus sequence at N278 
profoundly affected the efficient processing and trafficking of bADAM10. It 
is well known that the interaction of glycoproteins with the lectin 
chaperones from the ER, calnexin or calreticulin, is required for their correct 
folding, reviewed in (Helenius et al., 2003; Morais et al., 2003). The time 
that a certain glycoprotein remains in the calnexin/calreticulin folding cycle 
in the ER depends on the protein, and it can vary from minutes to hours. If 
glycoproteins fail to attain the correct fold, they can either be accumulated 
in the ER as aggregates, be translocated to the cytosolic face of the ER 
and be degraded by the proteasome, or they can be transported to the 
Golgi apparatus and divert to the lysosome where they are degraded 
(Helenius et al., 2003;Trombeta et al., 2003). Our results suggest that the 
N-linked glycans from N278 are important for the folding of the protein 
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probably mediating the interaction with calnexin. In the absence of this 
folding step ADAM10 would fail to attain its final conformation and would be 
retained in the ER. As a consequence the protein would remain as an 
inactive precursor protein not only because of impaired folding but also 
because further proteolytic processing to the mature form, which takes 
place in the Golgi, would not occur due to compartmentalization 
constraints. In agreement, T280A mutant showed reduced levels of activity 
both in vivo and in vitro. Since only the ADAM10 mature form is active 
(Schlondorff and Blobel, 1999; Seals and Courtneidge, 2003) the residual 
activity observed for this mutant is the result of the small amount of 
detected mature form. The 3D-model of ADAM10 metalloprotease domain, 
built using comparative modelling techniques based on the 3D structure of 
ADAM17, showed that the N278 site is located in an exposed zone and, 
therefore, has a good possibility of being occupied, which agrees with the 
experimental results. In addition, results obtained by other authors 
supported that ADAM10 N278 site is occupied in human platelets 
(Lewandrowski et al., 2006). Therefore, the N-linked glycans probably 
mediate interaction with calnexin. 
Mutation of the N439 glycosylation site resulted in increased 
susceptibility of bADAM10 to proteases. The 3D model of ADAM10 showed 
that N439 was found in an alpha-helix, which is a rare event but has a 
probability of occurring of 10.5% (Petrescu et al., 2004) that is a non-
negligible value. Therefore, mutation of this site probably induced a 
conformation alteration that exposed a particular region susceptible to 
protease degradation. Furthermore, since N439, as well as N267, are not 
located near the active site of ADAM10 from the 3D model, it is probable 
that mutating them did not have a direct effect on substrate binding, and 
therefore would not abolish enzyme activity, but could cause alterations in 
protein conformation, explaining the decreased activities. Changes in 
conformation caused by mutation of glycosylation sites with consequences 
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for activity have been described for other proteins, for example, the Kv3.1 
voltage-gated K+ channel (Brooks et al., 2006) or the GABA-transporter 1 
(Cai et al., 2005). 
N551 is located at the end of the disintegrin domain, juxtaposed to 
the Cys-rich domain. These domains have been described as mediators of 
protein-protein interactions and regulators of ADAM protease specificity 
(White, 2003). Furthermore, Janes et al. showed that the cystein-rich 
domain is the major responsible for substrate recognition and binding of the 
EphA3/ephrin complex (Janes et al., 2005). Even if the analysis of the 
crystallographic structure of the bADAM10 disintegrin and cystein-rich 
domains (PDB: 2ao7) showed that N551 is located away from the identified 
substrate recognition site, it is possible that mutating this site caused 
conformational changes of these domains leading to decreased substrate 
recognition specificities. This could explain the decreased in vivo activity of 
T553A. 
Signals responsible for the sorting of proteins into vesicles to be 
released as exosomes, within MVBs are still being elucidated. Mono-
ubiquitination of plasma membrane proteins acts as a signal for 
endocytosis and targeting to the endosomes. Furthermore, the 
sequestration of transmembrane proteins in exosomes could require 
(mono)-ubiquitination and the ESCRT-I, -II and -III protein complexes 
(reviewed in Keller et al., 2006; van Niel et al., 2006). Accordingly, in the 
present work, a comparatively higher amount of ubiquitinated proteins was 
found in the exosomes, and in particular, recombinant exosomal bADAM10 
appeared to be ubiquitinated. Concerning endogenous exosomal 
hADAM10, a fraction of the protein was detected at a higher molecular 
mass, which could be explained by ubiquitination or another post-
translational modification. In addition, this fraction exclusively presented 
complex N-glycans differently from total cellular hADAM10, which 
contained a mixture of complex and high mannose oligosaccharides. 
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Several possibilities can be admitted to explain this finding: i) more complex 
type glycoforms of hADAM10 are preferentially enriched during sorting and 
trafficking from the plasma membrane to the MVBs; ii) preferential 
enrichment of complex type glycoforms occurs during glycoprotein sorting 
into the exosomes; iii) increased proteolysis of less processed glycoforms 
occurs in the exosomes, thus revealing more processed glycoforms. 
Further experiments are required to clarify this matter, however, the low 
amounts of protein makes it a difficult task. 
An ADAM10 cleavage product was specifically found in exosomes 
and it was identified as being the result of metalloprotease cleavage. It is 
possible that the ADAM10 and the unidentified metalloprotease are 
specifically sorted into the exosomes and only get in contact there. 
In conclusion, the work described here provides evidence for the 
functional role of N-glycans from each of the N-glycosylation sites from 
ADAM10. They are required for the processing and activation of the 
enzyme, to protect the protein from proteolytic degradation, and, finally, 
they are required for full-enzyme activity. 
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carcinoma cells 
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3. Interaction and uptake of exosomes by ovarian 
carcinoma cells 
 
 
3.1. Summary 
 
Exosomes consist of membrane vesicles that are secreted by 
several cell types, including tumours and have been found in biological 
fluids. Exosomes interact with other cells and may serve as vehicles for the 
transfer of protein and RNA among cells. 
SKOV3 exosomes were labelled with carboxyfluoresceine diacetate 
succinimidyl-ester and collected by ultracentrifugation. Uptake of these 
vesicles, under different conditions, by the same cells from where they 
originated was monitored by immunofluorescence microscopy and flow 
cytometry analysis. Lectin analysis was performed to investigate the 
glycosylation properties of proteins from exosomes and cellular extracts. 
In this work, the ovarian carcinoma SKOV3 cell line has been shown 
to internalize exosomes from the same cells via several endocytic 
pathways that were strongly inhibited at 4 ºC, indicating their energy 
dependence. Partial colocalization with the endosome marker EEA1 and 
inhibition by chlorpromazine suggested the involvement of clathrin-
dependent endocytosis. Furthermore, uptake inhibition in the presence of 
5-ethyl-N-isopropyl amiloride, cytochalasin D and methyl-beta-cyclodextrin 
suggested the involvement of additional endocytic pathways. The uptake 
required proteins from the exosomes and from the cells since it was 
inhibited after proteinase K treatments. The exosomes were found to be 
enriched in specific mannose- and sialic acid-containing glycoproteins. 
Sialic acid removal caused a small but non-significant increase in uptake. 
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Furthermore, the monosaccharides D-galactose, α-L-fucose, α-D-mannose, 
D-N-acetylglucosamine and the disaccharide β-lactose reduced exosomes 
uptake to a comparable extent as the control D-glucose. 
In conclusion, exosomes are internalized by ovarian tumour cells via 
various endocytic pathways and proteins from exosomes and cells are 
required for uptake. On the other hand, exosomes are enriched in specific 
glycoproteins that may constitute exosome markers. This work contributes 
to the knowledge about the properties and dynamics of exosomes in 
cancer. 
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3.2. Introduction 
 
Exosomes are small membrane vesicles between 40-100 nm in 
diameter that are secreted by various cell types, including tumour cells, 
neurons, B- and T-lymphocytes, intestinal epithelial cells (Denzer et al., 
2000; Keller et al., 2006; Simpson et al., 2009), and in physiological fluids 
(Simpson et al., 2009; van Niel et al., 2006). 
Exosome biogenesis involves the inward budding of endosomes 
into MVBs to form intraluminal vesicles that are then released to the 
extracellular space. During this process transmembrane proteins are 
incorporated into the invaginating membrane maintaining the same 
topological orientation as the plasma membrane, while cytosolic 
components are engulfed. 
The molecular basis of protein sorting during exosome formation 
appears to involve an ubiquitin-dependent mechanism and the endosomal 
sorting complexes required for transport - ESCRT (Katzmman et al., 2001; 
Lakkaraju and Rodriguez-Boulan, 2008). However, some proteins present 
in the exosomes are not ubiquitinated, suggesting that other mechanisms 
such as oligomerization or partitioning of protein into lipid raft domains may 
be involved (Lakkaraju and Rodriguez-Boulan, 2008; de Gassart et al., 
2003; Schorey and Bhatnagar, 2008; Trajkovic et al., 2008). 
Exosomes are released by MVBs fusion with the plasma membrane 
and the mechanism appears to involve Rab27A and Rab27B (Ostrowski et 
al., 2010). Recent studies have suggested their participation in different 
physiological and/or pathological processes such as tumour progression, 
stimulation of the immune system, coagulation and inflammation, and 
intercellular transfer of infectious agents, such as proteins and RNA (van 
Niel et al., 2006; Lakkaraju and Rodriguez-Boulan, 2008; Schorey and 
Bhatnagar, 2008). 
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Many of the functions described for exosomes depend on their 
ability to specifically interact with a target cell and several types of 
interaction have already been proposed based on indirect evidence and in 
vitro studies. Exosomes can associate with the plasma membrane through 
ligand-receptor interactions (Théry et al., 2009) or lipids, such as 
phosphatidylserine (Keller et al., 2009). The process of internalization can 
occur through direct fusion of the exosomes with the plasma membrane, 
leading to the release of the exosomal content into the cell cytoplasm. 
Alternatively, exosomes can enter the cells by receptor-mediated 
endocytosis and later fuse with the limiting membrane of the endosome 
releasing the exosomal content to be recycled to the cell surface or to be 
degraded in the lysosome (Théry et al., 2009; Cocucci et al., 2009). 
Exosome uptake was shown to occur via clathrin-mediated endocytosis in 
dendritic cells (Morelli et al., 2004), as well as phagocytosis in monocytes 
and macrophages (Feng et al., 2010). 
Exosomes have a unique protein and lipid composition that varies 
depending on the cells from which they originate. Nevertheless, as a 
consequence of their endosomal origin nearly all exosomes contain 
proteins involved in membrane transport and fusion (RabGTPases, 
annexins, flotilin), in MVBs biogenesis (TSG101, Alix), heat shock proteins 
(Hsc70, Hsc90), integrins, and tetraspanins (CD9, CD63, CD81, CD82) 
(Simons and Raposo, 2009; Stoorvogel et al., 2002). In addition, they are 
enriched in raft-lipids such as cholesterol, sphingolipids, and ceramide. In 
exosomes, an enrichment of certain glycosylated motifs has also been 
observed (Krishnamoorthy et al., 2009). 
Glycosylation is a post-translational modification that plays an 
important role in several properties of proteins including stability, folding, 
intracellular trafficking, and recognition. Lectins and their interactions with 
carbohydrates have been found to play a role in exosome uptake by 
dendritic cells (Hao et al., 2007) and macrophages (Barres et al., 2010). 
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In the present work, the SKOV3 ovarian carcinoma cell line has 
been shown to internalize exosomes derived from the same cells via 
various endocytic pathways. Proteins from exosomes and from cells were 
required for the uptake. On the other hand, exosomes were highly enriched 
in specific glycosylated sialic acid- and mannose-containing glycoproteins, 
and sialic acid removal caused a small though non-significant increase in 
uptake. 
 
 
3.3. Materials and methods 
 
3.3.1. Cell culture 
 
Human ovarian cancer SKOV3, embryonic kidney HEK293, and 
neuroglioma H4 cell lines were grown in DMEM (Sigma) at 37 °C, 5% CO2 
supplemented with 10% fetal calf serum (Gibco), 1% penicillin/streptomycin 
solution (Gibco). 
 
3.3.2. Isolation of secreted membrane vesicles 
 
Confluent SKOV3, HEK293 and H4 cells were cultivated for 24 h in 
serum-free medium. The supernatant was collected and centrifuged, at 
500, 10,000 and 100,000 x g 10, 20 and 120 min, respectively, at 4 °C. The 
pellet of the last centrifugation consisted of secreted membrane vesicles. 
Sucrose-density fractionation was performed as described previously 
(Stoeck et al., 2006). 
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3.3.3. Glycoprotein detection using lectins and immunoblot 
 
Cellular extracts were obtained by solubilization of centrifuged cells 
in Triton X-100 buffer (50 mM Tris-HCl pH 7.5, 5 mM EDTA, 1% Triton X-
100, 0.02% complete protease inhibitors cocktail (Roche)), for 30 min. Total 
protein concentration was determined by the bicinchoninic acid (BCA) 
method. 
Glycoproteins from total cellular extracts and secreted membrane 
vesicles were stained after transfer to polyvinylidene difluoride (PVDF) 
membrane with lectins. Concanavalin A (Con A) (Sigma), biotinylated 
Sambucus nigra (SNA) and Maackia amurensis lectin (MAL) (Galab 
Technologies) were used. Glycoproteins were fixed on the PVDF 
membrane with 25% (v/v) 2-propanol and 10% (v/v) acetic acid for 5 min. 
The membranes were blocked for 1 h with TBS, 0.1% Tween-20 (TTBS) for 
Con A or with TTBS containing 2% BSA for SNA and MAL. For Con A 
detection the membrane was incubated overnight with 25 µg/ml Con A in 
TTBS containing 1 mM CaCl2 and 1 mM MgCl2 (TTBSS) followed by 1 h 
incubation with 0.5 µg/ml horseradish peroxidase type I (Sigma) in TTBSS. 
For SNA and MAL detection, membranes were incubated overnight in 
TTBS with 0.5 or 5 µg/ml SNA or MAL lectin, respectively. Membranes 
were further incubated for 1 h with 0.02 µg/ml streptavidin-peroxidase 
(Sigma). Detection was performed with the Immobilon Western 
chemiluminescent HRP substrate (Millipore). 
Immunoblot was performed as previously described (Chapter 2). 
The following antibodies were used: mouse anti-CD9 (1:5000) and mouse 
anti-L1 (L1 11A) (1:3). 
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3.3.4. Glycosidase treatment 
 
Hydrolysis of α2,3- and α2,6-linked NeuAc from total protein cellular 
extracts and exosomes was carried out overnight at 37 ºC by the addition of 
15 mU neuraminidase from Vibrio cholerae or from Arthrobacter urefaciens 
(Roche) in 50 mM sodium acetate pH 5.5 containing 4 mM CaCl2, and 50 
mM sodium acetate pH 5.0, respectively. For specific hydrolysis of α2,3-
linked NeuAc, 9 U neuraminidase from Streptococcus pneumonia 
(Prozyme, Glyko) in 50 mM sodium phosphate pH 6.0 were used, for 1 h at 
37 ºC. 
 
3.3.5. Uptake of SKOV3 exosomes by SKOV3 cells 
 
SKOV3 exosomes were labelled with carboxyfluoresceine diacetate 
succinimidyl-ester (CFSE) (Invitrogen) as previously described (Keller et 
al., 2009). Briefly, exosomes (20 µg) collected after a 100,000 x g 
ultracentrifugation were incubated with 7.5 µM CFSE for 30 min at 37 ºC in 
a final volume of 200 µl PBS containing 0.5% BSA. Labelled exosomes 
(Exos-CFSE) were 65-fold diluted with DMEM supplemented with 10% 
vesicles-free fetal calf serum and pelleted by ultracentrifugation for 16 h at 
10,0000 x g, 12 ºC. Exos-CFSE were resuspended in DMEM and incubated 
with SKOV3 cells at 37 or 4 ºC 
When indicated Exos-CFSE or cells were treated for 30 min with 
100 µg/ml proteinase K, or for 2 h with 15 mU neuraminidase from V. 
cholerae or from A. urefaciens, before uptake. SKOV3 cells were also 
incubated, 30 min prior to and during uptake, with the inhibitors 10 µg/ml 
chlorpromazine, 5 µg/ml cytochalasin D, 50 µM 5-ethyl-N-isopropyl 
amiloride (EIPA) or 2% methyl-beta-cyclodextrin, or with 150 mM of the 
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monosaccharides D-glucose, D-galactose, α-L-fucose, α-D-mannose, D-N-
acetylglucosamine, and the disaccharide β-lactose (Sigma). 
Uptake assays were always performed in the presence of the 
compounds and analyzed after 2 or 4 h by immunofluorescence 
microscopy or flow cytometry. 
 
3.3.6. Immunofluorescence microscopy 
 
Immunofluorescence microscopy was done as previously described 
(Chapter 2). Primary antibodies were: mouse IgG anti-alpha-tubulin DM1A 
(1:2000) (Sigma), mouse IgG anti-EEA1 (1:100) (BD Biosciences), mouse 
IgG anti-LAMP1 H4A3 (1:100) (BD Biosciences) and mouse IgG anti-
caveolin-1 (1:50) (Santa Cruz). Secondary antibody was donkey anti-
mouse IgG AlexaFluor 594 (1:500) (Molecular Probes). Images were 
acquired on a Leica DMRB microscope using a DFC340FX camera 
coupled to the microscope, and Leica application suite V3.3.0 software. For 
colocalization, images were acquired on a confocal SP5 microscope. Each 
picture was acquired with laser intensities and amplifier gains adjusted to 
avoid pixel saturation. Each fluorophore used was excited independently 
and sequential detection was performed. Each picture consisted of a z-
series of 20 images of 1024-1024 pixel resolution with a pinhole of 1.0 airy 
unit. Colocalization analysis was performed using the open source Image J 
version 1.38 (http://rsb.info.nih.gov/ij/). 
 
3.3.7. Flow cytometry 
 
SKOV3 cells incubated with Exos-CFSE for 4 h at 37 or 4 ºC were 
washed with PBS, detached using trypsin and resuspended in PBS with 2% 
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fetal calf serum (Gibco). Flow cytometry analysis was performed on a 
Cyflow ML cytometer (Partec) using Flowmax software 2.56 (Partec). Gate 
was set on living cells based on forward/side scatter properties and a 
minimum of 103 events within the gated live population were collected per 
sample. Exos-CFSE uptake by SKOV3 cells was measured by the shift in 
peak fluorescence intensity of CFSE, calculated by the geometric mean of 
the population. SKOV3 cells with no Exos-CFSE uptake (unlabelled) were 
used as controls for cell autofluorescence. Results were expressed as 
means ± S.D. and comparison between two means was performed by 
Student t-test. A p value lower than 0.05 was considered significant. 
 
 
3.4. Results 
 
3.4.1. Uptake of SKOV3 exosomes by SKOV3 cells 
 
Since it has been shown that SKOV3 exosomes can be internalized 
by NK cells (Keller et al., 2009) here we have investigated if they are 
internalized by the cell line from where they originated. With that purpose 
exosomes produced in the absence of fetal bovine serum and collected at 
100,000 x g were labelled with CFSE (Exos-CFSE) and incubated with 
SKOV3 cells. CFSE is a membrane permeable non-fluorescent compound 
that becomes fluorescent after cleavage of its acetate groups by 
intracellular esterases (Parish et al., 1999). A punctuated green fluorescent 
pattern corresponding to Exos-CFSE interaction/internalization was 
observed after 30 min and it increased up to 4 h of incubation (Figure 14, 
A). To obtain a higher sensitivity exosomes were also biotinylated and 
detected with streptavidin Alexa-488, and the interaction was observed 
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already 0.5 min after incubation (data not shown). Colocalization studies by 
immunofluorescence confocal microscopy of Exos-CFSE and alpha-tubulin, 
a microtubule marker, showed that Exos-CFSE were localized in the same 
z-stacks as microtubules, thus, confirming their internalization (Figure 14, 
B). Supporting this conclusion was the observation that the exosomes were 
not removed by acid wash of cells pre-exposed to Exos-CFSE (data not 
shown). 
 
 
 
 
 
 
 
 
 
 
 
Figure 14.   Uptake of SKOV3 exosomes by SKOV3 cells. (A) SKOV3 cells were 
incubated with Exos-CFSE (20 µg protein; green) for 4 h and were visualized in 
bright-field merged with fluorescence microscopy. Scale bar = 20 µm. (B) Detection 
of Exos-CFSE (green) and alpha-tubulin (red) by confocal immunofluorescence 
microscopy. Scale bar = 10 µm. 
 
 
Several endocytic mechanisms have been described to mediate the 
entry of material into the cells (Doherty et al., 2009). Here, we observed 
that a decrease in temperature from 37 to 4 ºC caused a reduction of 80 ± 
8% (n=6) in the number of labelled cells as well as a decrease of 77 ± 9% 
(n=6) in the uptake for the positively labelled cells, based on the shift in 
fluorescence intensity corresponding to the geometric mean of the 
population peaks (Figure 15, A). These results indicated that exosomes 
uptake was mediated by endocytosis in an energy-dependent process. 
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Exos-CFSE were also found to partially colocalize with the endosomal 
marker EEA1 (Figure 15, B), thus showing the participation of clathrin-
mediated endocytosis in exosome uptake. This conclusion was further 
supported by uptake inhibition (19 ± 18%, n=4) (Figure 15, C) with 10 µg/ml 
chlorpromazine, which blocks clathrin-mediated endocytosis (Wang et al., 
1993). Colocalization with the lysosomal marker LAMP1 (Figure 15, B) 
indicated that at least a part of the exosomes were targeted to the 
lysosome.  
In addition, other inhibitors have been tested. First, cells incubated 
with 5 µg/ml cytochalasin D, which is known to inhibit actin polymerization 
and consequently inhibit phagocytosis (deFife et al., 1999) as well as other 
endocytic pathways (Tian et al., 2010) showed an uptake reduction of 32 ± 
7% (n=4) (Figure 15, C). EIPA at 50 µM, which is known to block 
macropinocytosis (West et al., 1989), caused an uptake reduction of 36 ± 
13% (n=5) (Figure 15, C), thus suggesting that exosomes were internalized 
via macropinocytosis. Methyl-beta-cyclodextrin, that is used to deplete 
cholesterol from cellular membranes (Rodal et al., 1999), decreased Exos-
CFSE uptake (44 ± 8%, n=5) (Figure 15, C). However, there was no 
colocalization with caveolin-1 (Figure 15, B), which is a marker of caveolae 
that are enriched in cholesterol rich domains. These results indicated that 
exosome uptake could occur via a cholesterol associated pathway 
independent of caveolae or that methyl-beta-cyclodextrin affected 
exosomes membrane integrity, thus decreasing uptake efficiency. 
Exos-CFSE did not colocalize with the Golgi marker GM130, the 
trans-Golgi network marker TGN46 or the endoplasmic reticulum marker 
calnexin (data not shown). 
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Figure 15. Path of internalization of exosomes in SKOV3 cells. (A) Exos-CFSE 
(20 µg protein; green) were incubated with SKOV3 cells at 37 or 4 ºC and uptake 
was monitored by flow cytometry analysis of cell fluorescence intensity. Solid and 
dashed lines represent Exos-CFSE uptake at 37 and 4 ºC, respectively. (B) 
Colocalization of Exos-CFSE (20 µg protein; green) with EEA1 (red), LAMP1 (red), 
and caveolin-1 (red). Secondary antibody was donkey anti-mouse IgG AlexaFluor 
594. Colocalization is indicated in yellow. Images in the left bottom represent 4x 
magnifications of selected areas. Scale bars = 10 µm. (C) Effect of chlorpromazine, 
cytochalasin D, EIPA, and methyl-beta-cyclodextrin (30 min pre-incubation) on 
Exos-CFSE uptake (4, 4, 4 and 2 h, respectively) monitored by flow cytometry 
analysis (dashed lines). Controls consist of SKOV3 cells with no treatment for 
chlorpromazine and methyl-beta-cyclodextrin, or treated with DMSO for 
cytochalasin D and EIPA (solid lines). Unlabelled SKOV3 cells (grey) were used as 
control for cell autofluorescence. The results shown are representative of three 
independent experiments. 
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3.4.2. Proteins are required for exosomes uptake 
 
The recognition between exosomes and the target cell has been 
reported to involve proteins present at the cell surface of both exosomes 
and target cells (Théry et al., 2009; Morelli et al., 2004). Here, Exos-CFSE 
or SKOV3 cells were digested with proteinase K, a broad specificity 
protease, and uptake efficiency was analyzed by flow cytometry analysis. 
Uptake levels of digested Exos-CFSE were found to be lower (45 ± 12%, 
n= 6) than Exos-CFSE without treatment (Figure 16, A). As control, 
fluorescence of Exos-CFSE was not affected by proteinase K treatment 
(data not shown). Furthermore, a decrease of 32 ± 8% (n= 6) in uptake was 
observed in SKOV3 cells treated with proteinase K (Figure 16, B). 
Therefore, proteins present in exosomes and also in SKOV3 cells are 
required, at least in part, for internalization by target cells. 
 
 
 
Figure 16.  Effect of proteinase K treatment in SKOV3 exosomes uptake. (A) 
Exos-CFSE (20 µg protein; green) or (B) SKOV3 cells were treated with 100 µg/ml 
proteinase K for 30 min. Uptake was determined after 4 h of incubation by flow 
cytometry analysis and compared with uptake of Exos-CFSE with no treatment 
(solid lines). Unlabelled SKOV3 cells (grey) were used as control for cell 
autofluorescence. Dashed lines represent Exos-CFSE uptake after proteinase K 
digestion. The results shown are representative of three independent experiments 
performed in duplicate. 
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3.4.3. Enrichment of specific glycoproteins in exosomes and 
relevance in uptake 
 
Glycan-lectin interactions have been suggested to play a role in the 
uptake of exosomes by target cells (Hao et al., 2007; Barres et al., 2010), 
therefore, we have investigated if glycans would play a role in exosome 
uptake by SKOV3 cells. 
First, glycoproteins of cellular extracts and secreted vesicles from 
SKOV3 cells were detected with the lectins Con A (binds α-mannosyl 
containing branched glycans predominantly of the high-mannose followed 
by hybrid- and diantennary complex type structures to a lower extent) 
(Bhattacharyya et al., 1989), SNA (recognizes NeuAcα2,6Gal/GalNAc) and 
MAL (binds NeuAcα2,3Galβ1,4GlcNAc/Glc) (Knibbs et al., 1991).  
The profile from secreted vesicles was distinct from that of cellular 
extracts with the three lectins (Figure 17, A). Detection with SNA and MAL 
was almost totally abolished after digestion with V. Cholerae and A. 
urefaciens neuraminidases (cleave terminal α2,3- and α2,6-linked NeuAc), 
whereas only MAL binding was abolished after S. pneumoniae (cleaves 
only α2,3-linked NeuAc) digestion (Figure 17, B), thus confirming that SNA 
and MAL binding to secreted vesicles glycoproteins was specific. The sialic 
acid was not present in sialylated Lewis epitopes, since there was no 
detection with anti-sialyl-Lewisa or anti-sialyl-Lewisx antibodies (data not 
shown). 
SKOV3 secreted vesicles are constituted by exosomes and 
apoptotic vesicles, which can be fractionated by using a sucrose gradient, 
as previously described (Stoeck et al., 2006; Escrevente et al., 2008). CD9 
is a tetraspanin protein that has been used as exosome marker (Février 
and Raposo, 2004; Lamparski et al., 2002). After sucrose gradient 
separation of the secreted vesicles all the SNA and MAL binding was found 
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in the exosome-containing fractions (fractions 2-5) and not in the apoptotic 
blebs (fractions 8-11) (Figure 8, C).  
 
Figure 17.  Western blot and lectin detection of glycoproteins from SKOV3 
cellular extracts (Ext) and secreted vesicles (Ves). (A) Con A, SNA, and MAL 
lectin detection in SKOV3 cellular extract and vesicles. Three µg total protein were 
applied per lane. As positive controls, 200 ng ribonuclease B (RNase B) (Fu et al., 
1994), human plasma transferrin (TFR) (Spik et al., 1975) and erythropoietin 
(EPO
BRP
) (Sasaki et al., 1988) were used. (B) SNA and MAL lectin analysis of 
desialylated SKOV3 cellular extracts and vesicles. Total proteins (3 µg) were 
digested with neuraminidases from V. cholerae (Vb), A. urefaciens (Au) and S. 
pneumonia (Sp). Input consisted of cellular extracts and exosomes without 
treatment. As loading control L1 was detected. (C) Vesicles from 1.5x10
7
 SKOV3 
cells were fractionated in a sucrose gradient. Cellular extracts (Ext), secreted 
vesicles from 100,000 x g pellet (Ves), pooled fractions 2-5 (F2-5) (3 µg total 
protein), 20% of F1, F6-7, F8-11 and F12 were analysed. As positive control for 
exosomes, CD9 was detected. Detection was performed using the 
chemiluminescent method. 
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Specific patterns of protein glycosylation were also found for 
exosomes from two other human cell lines, embryonic kidney HEK293 and 
neuroglioma H4 cells (Figure 18).  
To investigate a possible role for glycosylation in exosome uptake 
Exos-CFSE were desialylated with V. cholerae and A. urefaciaens 
sialidases and exosomes uptake was monitored by immunofluorescence 
microscopy and flow cytometry analysis of cell fluorescence intensity. 
Uptake efficiency of exosomes after neuraminidase treatment was slightly 
increased (16 ± 14%, n= 6) when compared with exosomes incubated with 
neuraminidase buffer (Figure 19, A), however, the observed increase was 
not statistically significant using the Student t-test (p=0.0764). In addition, 
increases in the uptake of exosomes incubated with neuraminidase (38 ± 
13%, n=6) or neuraminidase buffer (23 ± 14%, n=6) were detected when 
compared with Exos-CFSE without treatment (Figure 19, A). 
 
 
Figure 18.  Con A, SNA, and MAL lectin detection of glycoproteins from 
HEK293 and H4 cellular extract (Ext) and secreted vesicles (Ves). For the 
analysis, 3 µg of total protein were applied per lane. Detection was performed 
using the chemiluminescent method. 
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The uptake assay was also performed in the presence of 150 mM of 
the monosaccharides D-glucose (control), D-galactose, α-L-fucose, α-D-
mannose and D-N-acetylglucosamine, and the disaccharide β-lactose. 
Decreases of 23 ± 7%, 24 ± 14%, 25 ± 16%, 27 ± 8%, 19 ± 15%, and 20 ± 
8% (n=6), respectively, in the uptake of Exos-CFSE in comparison with 
control without sugar were observed. The incubation with α-D-mannose led 
to a higher decrease in uptake relatively to the control sugar D-glucose, 
however the difference was not statistically significant (Figure 19, B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19.  Effects of neuraminidase and sugars on SKOV3 exosomes 
uptake. (A) Exos-CFSE (20 µg protein) were incubated with 15 mU V. cholera 
neuraminidase or corresponding buffer for 2 h before Exos-CFSE uptake. (B) 
Effect of 150 mM D-glucose (Glc), α-L-fucose (Fuc), α-D-mannose (Man), β- 
lactose (Lac), D-galactose (Gal) and D-N-acetylglucosamine (GlcNAc) (30 min pre 
incubation) on Exos-CFSE uptake (4 h) monitored by flow cytometry analysis. 
Uptake efficiency was calculated relatively to the uptake without treatment, 
considered as 100%. Results are displayed in relative percentages ± S.D. The 
results shown are representative of three independent experiments performed in 
duplicate. 
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3.5. Discussion 
 
Exosomes are small membrane vesicles that are secreted by 
several cell types, including tumours and they have been found in biological 
fluids. They contain several membrane and cytoplasmic proteins and, in 
cancer, they play a role in cell migration and metastases. They may also 
transfer proteins associated with deregulated signaling pathways in cancer 
(Al-Nedawi et al., 2008; Iero et al., 2007), therefore, contributing to the 
propagation of transformed phenotype. Furthermore, the exosomes may 
transfer mRNA and miRNA (Skog et al., 2008). 
In the present work, we have found that the SKOV3 ovarian 
carcinoma cell line internalizes exosomes derived from the same cells in an 
energy-dependent process, via various endocytic pathways: colocalization 
studies with organelle markers and incubation with inhibitors have shown 
that the endocytosis pathway dependent on clathrin, macropinocytosis, and 
a cholesterol associated pathway independent of caveolae were associated 
with the uptake. Evidence from the literature showed that in dendritic cells 
exosome uptake was also inhibited at 4 °C and with cytochalasin D, and 
was further trafficked to the late endosomes/lysosomes (Morelli et al., 
2004). In phagocytic cells, more specifically macrophages, internalization 
was also dependent on the actin cytoskeleton but not on pathways 
involving caveolae, macropinocytosis or clathrin coated vesicles (Feng et 
al., 2010). In the PC12 cell line exosomes uptake was also found to occur 
via the endocytic pathway (Tian et al., 2010). After internalization, 
exosomes could fuse with the endosomal membrane and deliver their 
content to the cytoplasm of the target cell. For SKOV3 cells such process 
could take place over a long period of time since internalized exosomes 
were detected in the cells for at least 20 h (data not shown). 
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The initial recognition events that precede uptake may involve 
several molecules, proteins (Simons and Raposo, 2009), and lipids (Keller 
et al., 2009) have already been indicated as involved in this process. In this 
work, the impairment observed for vesicles or cells treated with proteinase 
K indicated that proteins from the extracellular surface from both target 
cells and exosomes are required for internalization. Further studies to 
identify which proteins play an important role in the recognition are 
required. 
Here we also found that exosomes from SKOV3 cells are 
particularly enriched in specific glycoproteins with high mannose or 
NeuAcα2,3/6-containing structures. In this context, other authors, using 
lectin arrays, have also observed the enrichment in T-cells secreted 
microvesicles of high-mannose and sialic acid-containing structures in 
comparison with cell membranes (Krishnamoorthy et al., 2009). 
Furthermore, an enrichment of more extensively glycosylated forms of PrPc 
has been found in the exosomes in comparison with cell lysates (Vella et 
al., 2007). 
Removal of NeuAc from the exosomes with neuraminidase led to an 
increase in the uptake, but non-significant. The removal of NeuAc 
decreased the negative charge at the exosome surface exposing galactose 
or N-acetylgalactosamine residues. This could lead to physico-chemical 
alterations of the membrane or create new ligands for carbohydrate binding 
proteins at the surface of the cells that would mediate the binding. 
The monosaccharides D-galactose, α-L-fucose, α-D-mannose, D-N-
acetylglucosamine, and the disaccharide β-lactose reduced exosomes 
uptake to a comparable extent as the control D-glucose probably due to 
increased osmotic pressure that is known to reduce endocytosis (Oka et 
al.1989). Therefore, these sugars do not play a major role in exosome 
interaction and uptake in SKOV3 cells. This result is different from that 
found in dendritic cells where exosome uptake was specifically inhibited by 
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mannose and N-acetylglucosamine, the interaction being at least in part 
mediated by a C-type lectin (Hao et al., 2007), or in macrophages where 
lactose diminished exosome uptake probably through its action on galectin-
5 that mediated the process (Barres et al., 2010). 
Here, certain glycoproteins were specifically detected in exosomes 
and may constitute markers. It will be interesting to investigate if those 
glycoproteins are selectively sorted to the exosomes or if only certain 
glycoforms from the same protein are sorted into the exosomes. It can be 
admitted that glycans by themselves may be important for glycoprotein 
sorting into exosomes. Since protein oligomerization is known to promote 
sorting into exosomes independently of the ESCRT machinery and 
ubiquitination (Simons and Raposo, 2009), the glycans could mediate 
oligomerization via interaction with lectins as previously described for the 
transferrin receptor in reticulocytes (Vidal et al., 1997). Moreover, glycans 
may interact with galectins at the cell surface, which may lead to their 
enrichment in membrane lipid domains as previously described (Garner 
and Baum, 2008). Considering that lipid microdomains play a role on 
exosomes biogenesis (Simons and Raposo, 2009), glycans could in that 
case also have a role on sorting to exosomes. Further studies are required 
to clarify this matter. 
Exosomes contain cell surface cancer antigens, which confers them 
the potential for therapeutic approaches in cancer vaccination. Our 
observation that they are particularly enriched in glycan epitopes urges the 
need to further characterize the corresponding structures since one of the 
major changes that occur in cancer is in cell surface glycosylation, which 
has been largely used as biomarker. The knowledge of exosomes 
glycosylation with the possibility for its modulation will open new 
perspectives in cancer vaccination. 
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4. N-glycosylation of secreted vesicles from ovarian 
tumour cells 
 
 
4.1. Summary 
 
 Vesicles secreted from cells, including exosomes, are released by 
several cell types, including ovarian tumour cells, and are found in 
biological fluids such as malignant ascites and blood. They contain several 
membrane and cytoplasmic proteins and they play a role in cancer 
progression. 
 Aberrant glycosylation is an important aspect in malignant 
transformation and consequently in ovarian cancer. Exosomes from ovarian 
tumour cell lines have been shown to be enriched in specific glycoproteins 
in comparison with cellular extracts. Nevertheless, detailed knowledge 
about these glycan structures is not known at present.  
 In the present work, vesicles secreted from SKOV3 cells were 
compared with plasma membrane and microsomal enriched fractions and 
were found to contain specific glycoproteins that were distinctly recognized 
by the lectins Con A, SNA, MAL and Wisteria floribunda (WFA).  
 Detailed structure analysis of the N-glycans from SKOV3 and OVM 
secreted vesicles, microsomal, and plasma membrane fractions was 
performed by HPAEC-PAD and MALDI-TOF-MS. Complex glycans of di-, 
tri- and tetraantennary type with proximal fucose (Fuc) were found in all 
fractions of both cell lines. High mannose structures were enriched in the 
microsomal fraction of the two cell lines. Agalactosylated truncated 
structures were found predominantly in SKOV3 cells, while the terminal 
LacdiNAc motif was abundant in SKOV3-secreted vesicles.  
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The results obtained contributed to the knowledge of the 
glycosylation of vesicles secreted from ovarian tumour cells comparatively 
to other cellular membrane enriched fractions. This might open new 
perspective for the use of secreted vesicles as potential sources of tumour 
markers. 
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4.2. Introduction 
 
 Many cell types, including tumour cells, secrete exosomes into the 
extracellular space. These vesicles can also be found in the body fluids, 
such as blood, urine, saliva, and malignant effusions (reviewed in van Niel 
et al., 2006), and can contribute to tumour invasion and progression by 
transferring genetic information that confers aggressive phenotypes (Al-
Nedawi et al., 2008), modifying the tumour microenvironment (Castellana et 
al., 2009), conferring multi-drug resistance (Shedden et al., 2003; Safaei et 
al., 2005), and promoting angiogenesis, tumour growth and metastasis 
(reviewed in Muralidharan-Chari et al., 2010). Moreover, exosomes contain 
proteins related with tumour progression (Gutwein et al., 2005; Runz et al., 
2007) that might be used as tumour markers and also constitute potential 
targets for therapeutic approaches.  
Ovarian tumour cells were found to release large amounts of 
vesicles and the rate of their release has been shown to correlate with 
tumour invasiveness (Ginestra et al., 1999). Moreover exosomes were also 
found in blood (Taylor and Gercel-Taylor, 2008; Li et al., 2009) and 
malignant ascites (Gutwein et al., 2005; Runz et al., 2007) of patients with 
ovarian carcinoma.  
 Glycosylation alterations are typical for all kinds of cancers, 
including ovarian carcinoma, and include several changes related to 
terminal carbohydrate structures, such as incomplete synthesis and 
modification of normally existing carbohydrates, and changes in the 
carbohydrate core structures (Dabelsteen, 1996). Several studies have 
already described specific glycosylation changes in the serum of ovarian 
cancer patients. They include increased core fucosylated, agalactosylated 
complex-type diantennary glycans originated from immunoglobulin G, along 
with the sLex determinant (Saldova et al., 2007), increased sialylation with a 
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shift in sialic acid linkage from α2,3- to α2,6- in ovarian cancer serum 
glycoproteins (Saldova et al., 2007), and alterations in fucosylation and 
branching in α1-acid glycoprotein (Imre et al., 2008). 
Ovarian carcinoma cell lines, SKOV3, GG, OVM, and m130 were 
already characterized with respect to their glycosylation using anti-
carbohydrate antibodies and lectins (Escrevente et al., 2006). The cells 
contained variable amounts of Lewis carbohydrate motifs and all contained 
glycoproteins recognized by Con A, a lectin that binds α-mannosyl 
containing-branched glycans predominantly of the high mannose followed 
by hybrid and diantennary complex structures to a lower extent 
(Bhattacharyya et al., 1989), and SNA that binds structures containing 
terminal α2,6-linked sialic acid (Knibbs et al., 1991). In addition, structure 
analysis of the N-linked glycans from total glycoproteins derived from 
SKOV3 ovarian carcinoma cells confirmed the abundance of high mannose 
and proximally-fucosylated, complex type partially agalactosylated glycan 
structures, as well as the presence of the LacdiNAc motif (Machado et al., 
2011). 
 SKOV3 cells exosomes have been shown to contain higher levels of 
certain glycosylated sialic acid- and mannose-containing glycoproteins 
when compared with total cellular extracts (Chapter 3). Nevertheless, 
detailed knowledge about the N-glycan structures and their role is not 
elucidated at present.  
 Lectin binding assays using Con A, SNA, MAL and WFA revealed 
that secreted vesicles have a unique glycosylation profile when compared 
with plasma membrane, and microsomal enriched fractions. The N-glycan 
analysis from SKOV3 and OVM secreted vesicles, plasma membrane and 
microsomal fractions by HPAEC-PAD and MALDI-TOF-MS showed that all 
fractions of both cell lines contained complex glycans of di-, tri- and 
tetraantennary type with proximal Fuc. Furthermore, high mannose type 
structures were found to be enriched in the microsomal fraction of the two 
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cell lines. Agalactosylated truncated structures were found predominantly in 
SKOV3 cells. Finally, the terminal LacdiNAc motif was abundant in 
secreted vesicles of SKOV3 cells.   
 
 
4.3. Materials and methods 
 
4.3.1. Cell culture 
 
 Human ovarian cancer SKOV3, OVM, m130, and GG cell lines were 
grown in DMEM (Sigma) at 37 °C, 5% CO2, supplemented with 10% fetal 
calf serum (Gibco), and 1% penicillin/streptomycin solution (Gibco). 
 
4.3.2. Isolation of cell-secreted vesicles  
 
 Cell-secreted vesicles were isolated as previously described 
(Chapter 3). Briefly, confluent SKOV3, OVM, m130 and GG cells were 
cultivated for 48 h in serum-free medium. The supernatant was collected 
and centrifuged at 500, 10,000 and 100,000 x g, 10, 20 and 120 min, 
respectively, at 4 °C. The pellet of the last centrifugation, consisting of 
secreted membrane vesicles, was resuspended in PBS.  
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4.3.3. Isolation of microsomal and plasma membrane enriched 
fractions 
 
 The isolation of the microsomal membrane fraction from SKOV3 
and OVM cells was accomplished by differential centrifugation. Cells were 
pelleted by centrifugation, washed once with PBS, and resuspended in 
homogenization buffer (1 mM NaHCO3, 0.2 mM CaCl2, 0.2 mM MgCl2, 
1mM spermidine, pH 8). Cells were disrupted with a pellet pestle (Sigma) 
and centrifuged at 600 x g, 10 min, 4 ºC. Supernatant was collected and 
further centrifuged at 15,000 x g and 100,000 x g, for 10 and 120 min, 
respectively, at 4 ºC. The pellet, consisting of the microsomal membrane 
fraction was homogenised in PBS with a 25 gauge needle until complete 
resuspension. The supernatant containing the cytosolic fraction was also 
collected for further analysis. 
 The isolation of plasma membrane proteins from SKOV3 and OVM 
cells was performed by cell surface biotinylation. SKOV3 cells were washed 
with PBSCM (1 mM CaCl2, 1 mM MgCl2 in PBS) and biotinylated with 0.5 
mg/ml sulfo-NHS-SS-biotin (Pierce) in PBSCM for 40 min at 4 ºC with 
agitation (Sousa et al., 2003). After a two fold wash with PBSCM containing 
50mM NH4Cl followed by DMEM with 10% FCS and 1% P/S, cells were 
incubated with lysis buffer (1% Triton-X, 0.5% DOC, 0.1% SDS, 5 mM 
EDTA, 0.02% complete protease inhibitors cocktail (Roche)) for 30 min at 4 
ºC with agitation. After centrifugation the supernatants were incubated with 
streptavidin-agarose beads (Sigma) for 2 h, at 4 ºC to pellet biotinylated 
proteins. The agarose beads were pelleted and washed four times with 
washing buffer (10 mM Tris-HCl buffer pH 8.0, 0.5 M NaCl, 1 mM EDTA 
and 1% NP-40). Biotinylated proteins were eluted by incubation in 0.08% 
Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 5 min at 100 ºC. Non-biotinylated 
proteins were also collected from the supernatant for further analysis. 
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4.3.4. Glycoprotein detection using lectins and immunoblot 
 
 Cellular extracts were obtained by solubilization of centrifuged cells 
in Triton X-100 buffer (50 mM Tris-HCl pH 7.5, 5 mM EDTA, 1% Triton X-
100, 0.02% complete protease inhibitors cocktail (Roche)) for 30 min. 
Secreted vesicles, plasma membrane, and microsomal fractions were 
obtained as described above.  
 Total protein concentration was determined by the BCA method. 
Glycoproteins were stained after transfer to PVDF membrane with lectins. 
Con A (Sigma), biotinylated SNA, MAL (Galab Technologies), and WFA 
(Vector Labs) were used. Glycoproteins were fixed on the PVDF membrane 
with 25% (v/v) 2-propanol and 10% (v/v) acetic acid for 5 min. The 
membranes were blocked for 1 h with TBS, 0.1% Tween 20 (TTBS) for Con 
A, with TTBS containing 2% BSA for SNA, and MAL and with TBS, 0.15% 
Tween 20, 2% BSA for WFA. For Con A detection the membrane was 
incubated overnight with 25 µg/ml Con A in TTBS containing 1 mM CaCl2 
and 1 mM MgCl2 (TTBSS) followed by 1 h incubation with 0.5 µg/ml 
horseradish peroxidase type I (Sigma) in TTBSS. For SNA, MAL and WFA 
detection, membranes were incubated overnight in TTBS with 0.5 µg/ml 
SNA or 5 µg/ml MAL and WFA lectin. Membranes were further incubated 
for 1 h with 0.02 µg/ml streptavidin-peroxidase (Sigma).  
 When indicated, membranes were incubated simultaneously with 
the lectin and the corresponding competitive sugar, 0.2 M methyl-α-D- 
mannopyranoside for Con A and 0.2 M N-acetyl-D-galactosamine for WFA. 
Detection was performed with the Immobilon Western chemiluminescent 
HRP substrate (Millipore). 
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4.3.5. Total N-glycans isolation 
  
 Total N-glycans isolation from SKOV3 and OVM cell-secreted 
vesicles, microsomal, and plasma membrane fractions were performed as 
previously described (Machado et al., 2011). A total of 3.5 and 3 mg of total 
proteins corresponding to secreted vesicles and microsomal fraction, 
respectively, were solubilized for 30 min in PBS containing 2% (v/v) 
Nonidet P-40 and 0.1% benzonase (Sigma), pH 7.2. For the isolation of N-
glycan from the plasma membrane, a solution containing 350 µg of 
biotinylated proteins were used. Proteins were precipitated with 4 volumes 
of ice-cold 100% ethanol for 2 h at −20 °C and dried in a Speed Vac 
concentrator (Savant Instruments Inc.). The resulting pellet was incubated 
for 90 min in 0.3 M Tris–HCl pH 8.3, 6 M urea, 1 mM dithioerythritol, diluted 
in water and incubated overnight with 70 µg of trypsin (Merk) and 0.02% 
sodium azide.  
 Trypsin inactivation was accomplished by 10 min incubation at 90 
°C, followed by the addition of 0.02% complete protease inhibitor cocktail 
during 1 h. Next, the sample solution was subjected to buffer exchange 
using a 5 kDa Vivaspin concentrator (Sartorius) to PNGase F buffer (10 
mM NaH2PO4, 5 mM ethylenediaminetetraacetic acid, pH 7.5). All 
incubations were performed at room temperature unless otherwise noted. 
 The N-glycan release from total glycopeptides of secreted vesicles, 
microsomal, and membrane fractions from SKOV3 cells were performed by 
overnight incubation with 50 U PNGase F (Roche) at 37 °C. The released 
N-glycans were separated from the glycoproteins by precipitation with 2.4 
volumes of ice-cold 100% ethanol for 2 h at −20 °C. After centrifugation at 
10,000 × g, for 10 min at 4 °C, the N-glycans in suspension were removed, 
and two additional washes of the glycoprotein pellet were made with ice-
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cold 50% ethanol. The supernatants containing N-glycans were pooled and 
dried in a Speed Vac concentrator. 
 
4.3.6. Analysis of desialylated N-glycans by HPAEC-PAD 
  
 The N-glycan samples were desalted using 100 mg Hypercarb 
cartridges (Thermo) previously washed with 80% (v/v) acetonitrile (ACN) 
with 0.1% trifluoroacetic acid (TFA), and six times with water. The N-
glycans solubilized in water were then loaded onto the column, washed two 
times with water, and finally eluted with 40% ACN with 0.1% TFA. The 
eluted glycans were neutralized with 2.5% (v/v) NH4OH and dried in a 
Speed Vac concentrator. The desialylated N-glycans were prepared by 
incubation with 5 mM H2SO4 for 90 min at 80 °C. Hydrolyzed N-glycans 
were neutralized with 50 mM NaOH and dried in a Speed Vac concentrator. 
 The analysis of N-glycan structures by HPAEC-PAD was performed 
using an ICS-3000 ion chromatography system (Dionex Corporation), 
consisting of an AS autosampler, a DC detector/chromatography module, 
and a DP dual pump. Samples of 20 µL were injected into an equilibrated 
CarboPac PA200 column equipped with a guard column (3 × 50 mm, 
Dionex). Released desialylated N-glycans were eluted by using a 
concentration gradient of 0.15 M sodium hydroxide (solvent A) and 0.15 M 
sodium hydroxide/0.6 M sodium acetate (solvent B), at a flow rate of 0.4 
mL/ min. The gradient consisted of a 30 min isocratic run at 100% solvent 
A, followed by increasing solvent B concentration (10 min to 15%, 2 min to 
30%, 3 min to 100%). The column temperature was constant at 30 °C. The 
electrochemical detection of the oligosaccharides was performed by 
application of the detection potentials and durations as recommended by 
the manufacturer. 
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 For subsequent MALDI-TOF-MS analysis pools or individual 
fractions from the HPAEC-PAD analysis were collected after online 
desalting using a carbohydrate membrane desalter device (CMD-I, Dionex). 
Glycan fractions were dried in a Speed Vac concentrator for further 
analysis. 
 
4.3.7. Analysis of N-glycans by MALDI-TOF-MS 
 
 Glycans were analyzed with a Bruker ULTRAFLEX time-of-flight 
(TOF/TOF) instrument in the linear positive ion mode. Native desialylated 
oligosaccharides were analyzed using a matrix of 2,5-dihydroxybenzoic 
acid as a UV-absorbing material. Samples of 1 µL at an approximate 
concentration of 1–10 pmol/µL were mixed with equal amounts of the 
respective matrix and sodium salt. This mixture was spotted onto a 
stainless steel target and dried at room temperature before analysis. 
Structures were tentatively assigned to various N-glycans based on their 
observed masses compared with the calculated masses of known N-
glycans. 
 Mass spectrum data were analyzed with the Bruker DataAnalysis 
version 4 (Bruker Daltonics). Further annotation of N-glycans and database 
searches were performed using the GlycoWorkbench software (Ceroni et 
al., 2008). 
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4.4. Results 
 
4.4.1. Enrichment of specific glycoproteins in ovarian carcinoma 
secreted vesicles  
 
 SKOV3-secreted vesicles and exosomes were found to be highly 
enriched in certain glycosylated sialic acid- and mannose-containing 
glycoproteins when compared with total cellular extracts (Chapter 3). To 
investigate if secreted vesicles had a characteristic glycosylation profile that 
was distinct from plasma membrane and microsomal fractions, the different 
fractions were detected with lectins after Western blotting.   
 In this study, secreted vesicles isolated by ultracentrifugation of cell 
supernatants at 100,000 x g were used for analysis since this fraction has 
been shown to be enriched in exosomes (Théry et al., 2006). Previous 
results from our laboratory have shown that MAL- and SNA-binding 
glycoproteins were only detected in exosome-containing fractions after 
sucrose density purification (Chapter 3).  
 The microsomal fraction was obtained by differential centrifugation 
and it consisted of the 100,000 x g pellet after clarification of the cell extract 
at 15,000 x g, while a plasma membrane  enriched fraction was obtained by 
cell surface protein biotinylation and separation with streptavidin-agarose. 
As controls, a cytoplasmic fraction consisting of post-100,000 x g 
supernatant, and an intracellular fraction containing proteins that were not 
biotinylated were also analysed. 
 Glycoproteins of SKOV3 cellular extracts (Ext), secreted vesicles 
(Ves), and all the other enriched fractions were detected with the lectins 
Con A, SNA, MAL and WFA (recognizes the LacdiNAc motif, 
GalNAcβ4GlcNAc). The glycosylation profile of SKOV3-secreted vesicles 
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was distinct from all other fractions with all the lectins tested (Figure 20). 
Con A was shown to strongly bind glycoproteins of SKOV3-secreted 
vesicles when compared with other fractions, using the same amount of 
total protein. The binding specificity was confirmed using 0.2 M of the 
competitive sugar methyl-α-D-mannopyranoside. 
 In SKOV3 cell secreted vesicles three glycoproteins with sizes of 
approximately 260 kDa and one with about 110 kDa were recognized by 
WFA (indicated with asterisks in Figure 20). In the plasma membrane 
enriched fraction only one specific glycoprotein at approximately 160 kDa 
was recognized. The detection was specific since it was abolished in the 
presence of 0.2 M of competitive sugar N-acetyl-galactosamine. The signal 
detected in cellular extracts, microsomal, intracellular, and cytoplasmic 
fractions with WFA was probably not specific since it was not inhibited after 
incubation with the competitive sugar (Figure 20).  
 Previous results have shown that specific bands from SKOV3 
exosomes were strongly recognized by SNA and MAL contrary to cellular 
extracts (Chapter 3). In the present study, SKOV3-secreted vesicles 
contained two major bands identified by SNA, one with an apparent 
molecular mass of 260 kDa and the second between 80 and 110 kDa 
(indicated with asterisks in Figure 20).  MAL detected two bands with high 
intensity in SKOV3-secreted vesicles, one band around 260 kDa and a 
second band between 110 and 160 kDa (indicated with asterisks in Figure 
20). These specific glycoproteins were not found in microsomal or plasma 
membrane enriched fractions (Figure 20). Therefore, sialylated 
glycoproteins identified were specific to secreted vesicles, and were not 
found in other membrane fractions. 
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Figure 20. Western blot and lectin detection of glycoproteins from SKOV3 
cellular extracts (Ext), microsomal fraction (MF), plasma membrane fraction 
(PM), intracellular fraction (IC), cytoplasmic fraction (Cyt) and secreted 
vesicles (Ves). Detection of glycoproteins with Con A, WFA, SNA and MAL. 
Competitive sugars used were 0.2 M methyl-α-D-mannopyranoside for Con A and 
0.2 M N-acetyl-galactosamine for WFA. Total proteins (3 µg) were applied per lane. 
Detection was performed using the chemiluminescent method. Asterisks 
correspond to most abundant glycoproteins enriched in the secreted vesicles. 
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 To determine if there was also an enrichment of specific sialic acid-
containing glycoproteins in other ovarian carcinoma cell lines, secreted 
vesicles from OVM, m130, and GG cells were analysed by Western blot 
with SNA and MAL (Figure 21). SNA was found to bind specific 
glycoproteins in m130 secreted vesicles, including one protein above 260 
kDa, one with approximately 160 kDa and three proteins with apparent 
molecular masses around 80 kDa (indicated with asterisks in Figure 21). 
MAL detected one major glycoprotein in m130 and OVM secreted vesicles 
with about 110 kDa (indicated with asterisks in Figure 21). No specific 
enrichment was observed for GG cells with these lectins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21.  Western blot and SNA and MAL lectin detection of glycoproteins 
from OVM, m130 and GG ovarian carcinoma cell lines. For the analysis, three 
µg of total proteins from cellular extracts (Ext) and secreted vesicles (Ves) were 
applied per lane. Detection was performed using the chemiluminescent method. 
Asterisks correspond to most abundant glycoproteins enriched in the secreted 
vesicles.  
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4.4.2. Structural analysis of desialylated N-glycans from ovarian 
tumour secreted vesicles, plasma membrane and microsomal 
fractions 
 
 To further elucidate the glycan structures of secreted vesicles 
comparatively to cellular membranes, the N-linked oligosaccharides of 
SKOV3 and OVM cell-secreted vesicles, plasma membrane, and 
microsomal enriched fractions were released with PNGase                              
F, desialylated by mild acid hydrolysis and were analyzed by HPAEC-PAD 
(Figure 22, C, D, and E) 
 The majority of the peaks eluted in the region of the chromatogram 
corresponding to high mannose: Man5GlcNAc2, Man6GlcNAc2, 
Man7GlcNAc2, Man8GlcNAc2 and Man9GlcNAc2 (9-18 min) (Figure 22, A 
and Figure 23, A) and complex N-glycans di-, tri-, and tetraantennary with 
and without LacNAc repeats and proximal Fuc (12-21 min) (Figure 22, B 
and Figure 23, B).  
 The HPAEC-PAD profile of secreted vesicles from SKOV3 and 
OVM cells was distinct from those of plasma membrane and microsomal 
fractions. For example, the microsomal fraction showed peaks with 
retention times identical to those of high mannose glycans contrary to other 
fractions (indicated with asterisks in Figure 22 and Figure 23). 
 Differences between the N-glycans profile of SKOV3 and OVM 
vesicles were also detected. For example, OVM vesicles showed a 
relatively larger peak co-eluting with tetraantennary glycans with proximal 
Fuc (Standard D, Figure 22 and Figure 23).  
 SKOV3 and OVM plasma membrane and microsomal fractions 
shared some similarities in their N-glycans profile, namely, a high intensity 
peak with a retention time of approximately 21 min that was almost 
undetected in the secreted vesicles (Figure 22 and Figure 23). 
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Figure 22. HPAEC-PAD analysis of the desialylated N-glycans released from 
SKOV3-secreted vesicles, plasma membrane and microsomal fractions. (A) 
High mannose glycan standards from RNase B, structures are: M5, Man5GlcNAc2; 
M6, Man6GlcNAc2; M7, Man7GlcNAc2; M8, Man8GlcNAc2; M9, Man9GlcNAc2. (B) 
Complex reference glycan standards from erythropoietin from chinese hamster 
ovary cells, structures (all proximally α6-fucosylated) are: A, diantennary; B, 2,4-
triantennary; C, 2,6-triantennary; D, tetraantennary; E, triantennary + one LacNAc 
repeat; F, tetraantennary + one LacNAc repeat; G, triantennary + two LacNAc 
repeats; H, tetraantennary + two LacNAc repeats; I, triantennary + three LacNAc 
repeats and tetraantennary + three LacNAc repeats. (C) Total N-glycans of 
SKOV3-secreted vesicles (Ves). Fractions a–j were subjected to MALDI-TOF-MS 
analysis (D) Total N-glycans of SKOV3 plasma membrane (PM) enriched fraction. 
(E) Total N-glycans of SKOV3 microsomal fraction (MF). Peaks indicated with an 
asterisk correspond to high mannose glycans. 
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Figure 23. HPAEC-PAD analysis of the desialylated N-glycans released from 
OVM secreted vesicles, plasma membrane and microsomal fractions. (A) High 
mannose glycan standards from RNase B, structures are: M5, Man5GlcNAc2; M6, 
Man6GlcNAc2; M7, Man7GlcNAc2; M8, Man8GlcNAc2; M9, Man9GlcNAc2. (B) 
Complex reference glycan standards from erythropoietin from Chinese hamster 
ovary cells, structures (all proximally α6-fucosylated) are: A, diantennary; B, 2,4-
triantennary; C, 2,6-triantennary; D, tetraantennary; E, triantennary + one LacNAc 
repeat; F, tetraantennary + one LacNAc repeat; G, triantennary + two LacNAc 
repeats; H, tetraantennary + two LacNAc repeats; I, triantennary + three LacNAc 
repeats and tetraantennary + three LacNAc repeats. (C) Total N-glycans of OVM-
secreted vesicles (Ves). Fractions k-p were subjected to MALDI-TOF-MS analysis 
(D) Total N-glycans of OVM plasma membrane (PM) enriched fraction. (E) Total N-
glycans of OVM microsomal fraction (MF). Peaks indicated with an asterisk 
correspond to high mannose glycans. 
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 Due to the high complexity of the samples and to obtain more 
structural information, the total desialylated N-glycan pool released from 
SKOV3 and OVM cell-secreted vesicles, plasma membrane, and 
microsomal enriched fractions were analysed by MALDI-TOF-MS (Figure 
24 and Figure 25). Furthermore, individual fractions of SKOV3 (a-j) (Figure 
22, C) and OVM (k-p) (Figure 23, C) vesicles from the HPAEC-PAD profiles 
were also collected after on-line desalting and were analysed by MALDI-
TOF-MS (Supplementary Figure 1 and Supplementary Figure 2). The 
results of the observed m/z and possible glycan structures, compatible with 
the proposed compositions and considering the N-glycosylation 
biosynthetic pathway of mammalian cells, are indicated in Table I and 
Table II for SKOV3 and OVM cells, respectively. 
 The major findings were as follows. Signals at m/z 1809.7, 2174.8 
and 2539.9 were compatible with complex glycans of the di-, tri- and 
tetraantennary type with proximal Fuc and they were detected for the 
secreted vesicles as well as in the plasma membrane and microsomal 
fractions. The results were found in the two cell lines (Figure 24 and Figure 
25).  
 Signals at m/z 1419.5, 1581.6, 1743.6 and 1905.6, compatible with 
high mannose structures (Man6GlcNAc2; Man7GlcNAc2; Man8GlcNAc2 and 
Man9GlcNAc2, respectively) were predominantly found in the microsomal 
fraction of the two cell lines (Figure 24, C and Figure 25, C).  
 Peaks at m/z 2012.5 and 1850.5 were compatible with 
agalactosylated truncated structures (triantennary minus one Gal and two 
Gal, respectively). Peaks at m/z 2377.6 and 2215.6 were compatible with 
tetraantennary glycans less one Gal and two Gal, respectively. These 
peaks were predominantly found in SKOV3 cells, in all fractions (Figure 24, 
A-C and Table I). For OVM cells they were found in minor amounts and 
only in the vesicles fraction (Figure 25, A-C and Table II).  
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 Peaks at m/z 1850.5, 2215.6 and 2580.7 in SKOV3-secreted 
vesicles could also correspond to complex glycans of the di-, tri- and 
tetraantennary type bearing the LacdiNAc motif (Figure 24, A). This 
hypothesis agrees with the detection of SKOV3-secreted vesicles with the 
lectin WFA (Figure 20). These peaks were absent from OVM plasma 
membrane and microsomal fractions and had a low intensity (1850.5, 
2215.6) or were absent (2580.7) from OVM-secreted vesicles (Figure 25, 
A).  
 The profiles for secreted vesicles were shown to be more 
heterogeneous than in the other fractions for the two cell lines. For OVM 
cells a comparatively higher amount of higher antennarity, tri- and 
tetraantennary glycans, relatively to diantennary glycans was detected in 
secreted vesicles versus plasma membrane or microsomal fractions 
(Figure 23 and Figure 25).  
 
 
 
 
Chapter 4 
108 
 
 
Figure 24. MALDI-TOF-MS analysis of the total desialylated N-glycans from 
SKOV3 cells. (A) secreted vesicles (Ves), (B) plasma membrane fraction (PM), (C) 
microsomal fraction (MF). Only one or two possible isomeric structures of selected 
peaks are presented. Graphical representations of glycans are consistent with the 
nomenclature of the Consortium for Functional Glycomics. 
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Figure 25. MALDI-TOF-MS analysis of the total desialylated N-glycans from 
OVM cells. (A) secreted vesicles (Ves), (B) plasma membrane fraction (PM), (C) 
microsomal fraction (MF). Only one or two possible isomeric structures of selected 
peaks are presented. Graphical representations of glycans are consistent with the 
nomenclature of the Consortium for Functional Glycomics. 
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Plasma Microsomal
Calculated membrane fraction
[M+Na]
+
HPAEC-PAD
fraction
1257.4 1257.5 b, c - - HexNAc2Hex5
1298.5 1298.4* a - - HexNAc3Hex4
1419.5 1419.4 d, e - 1419.5 HexNAc2Hex6
1444.5 1444.5* a - - HexNAc3Hex4dHex
1485.5 1485.4 a - - HexNAc4Hex3dHex
1581.5 1581.4 f, h 1581.6 1581.6 HexNAc2Hex7
1606.6 1606.5* c - - HexNAc3Hex5dHex
1647.6 1647.5 c, a, b, h 1647.6 - HexNAc4Hex4dHex
1663.6 1663.4 e 1663.6 1663.6 HexNAc4Hex5
1688.6 1688.5 c - - HexNAc5Hex3dHex
1704.6 1704.5* e - - HexNAc5Hex4
1743.6 1743.4 g, h 1743.5 1743.6 HexNAc2Hex8
1809.7 1809.5 d, c, e, f, h 1809.6 1809.7 HexNAc4Hex5dHex
1850.7 1850.5 a, d, c, e 1850.6 1850.7 HexNAc5Hex4dHex
1866.6 1866.6* f 1866.7 1866.7 HexNAc5Hex5
m/z m/z
Proposed composition Compatible structure
Vesicles
m/z
Table I. Observed mass signals (m/z) by MALDI-TOF-MS analysis. Proposed 
composition and compatible structure of the major desialylated N-glycans from 
SKOV3 cells. 
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Plasma Microsomal
Calculated membrane fraction
[M+Na]
+
HPAEC-PAD
fraction
1905.6 1905.6* h, i - 1905.6 HexNAc2Hex9
1996.7 1996.7* a - - HexNAc5Hex4dHex2
2012.7 2012.5 f, e, g, h 2012.7 2012.7 HexNAc5Hex5dHex
2028.7 2028.5 i, j, g, h 2028.7 2028.7 HexNAc5Hex6
2053.8 2053.6* b - - HexNAc6Hex4dHex
2158.8 2158.7* a - - HexNAc5Hex5dHex2
2174.8 2174.6 f, g, h, i 2174.7 2174.8 HexNAc5Hex6dHex
2215.8 2215.6 c, f, h - 2215.8 HexNAc6Hex5dHex
2377.9 2377.6 g, h, i, j 2377.8 2377.8 HexNAc6Hex6dHex
2393.8 - - - 2393.8 HexNAc6Hex7
2523.9 2523.8* b - - HexNAc6Hex6dHex2
2539.9 2539.6 h, i, j 2539.8 2539.9 HexNAc6Hex7dHex
2580.9 2580.7 h, i - - HexNAc7Hex6dHex
m/z m/z
Proposed composition Compatible structure
Vesicles
m/z
Table I. Observed mass signals (m/z) by MALDI-TOF-MS analysis. Proposed 
composition and compatible structure of the major desialylated N-glycans from 
SKOV3 cells (continued). 
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Plasma Microsomal
Calculated membrane fraction
[M+Na]
+
HPAEC-PAD
fraction
2743.0 2742.7 i, j 2742.9 2743 HexNAc7Hex7dHex
2905.0 2904.8 j, i - 2905 HexNAc7Hex8dHex
3108.1 3108.1* j - - HexNAc8Hex8dHex
3270.0 3270.1* j - - HexNAc8Hex9dHex
3473.2 3473.2* j - - HexNAc9Hex9dHex
m/z m/z
Proposed composition Compatible structure
Vesicles
m/z
Table I. Observed mass signals (m/z) by MALDI-TOF-MS analysis. Proposed 
composition and compatible structure of the major desialylated N-glycans from 
SKOV3 cells (continued). 
 
 
 
HexNAc, N-acetylhexosamine (GlcNAc/GalNAc); dHex, deoxyhexose (Fuc); Hex, 
hexose (Man or Gal). Asterisk denotes compound only detected in the MALDI-
TOF-MS analysis of the separated fractions from the HPAEC-PAD analysis (Figure 
22, C). Letters underlined represent the HPAEC-PAD fractions where m/z signal 
was predominantly observed. Only one or two possible glycan structures, 
compatible with the proposed compositions, are shown. Graphical representations 
of glycans are consistent with the nomenclature of the Consortium for Functional 
Glycomics. 
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Plasma Microsomal
Calculated membrane fraction
[M+Na]
+
HPAEC-PAD
fraction
1257.4 1257.4* k, l - - HexNAc2Hex5
1339.5 1339.5* k - - HexNAc4Hex3
1419.5 1419.5* m - 1419.5 HexNAc2Hex6
1444.5 1444.5* k - - HexNAc3Hex4dHex
1485.5 1485.6* k, l - - HexNAc4Hex3dHex
1501.5 1501.6* l - - HexNAc4Hex4
1581.5 1581.4 n, o 1581.5 1581.6 HexNAc2Hex7
1606.6 1606.6* l - - HexNAc3Hex5dHex
1647.6 1647.4 l, k 1647.6 - HexNAc4Hex4dHex
1663.6 1663.4 m, n, p 1663.6 1663.6 HexNAc4Hex5
1688.6 1688.4 l - - HexNAc5Hex3dHex
1743.6 1743.6* o 1743.5 1743.6 HexNAc2Hex8
1768.6 1768.4* n - - HexNAc3Hex6dHex
1809.7 1809.4 m, l, n 1809.6 1809.7 HexNAc4Hex5dHex
1850.7 1850.5 k, m - - HexNAc5Hex4dHex
Vesicles
Proposed composition Compatible structure
m/z m/z m/z
Table II. Observed mass signals (m/z) by MALDI-TOF-MS analysis. Proposed 
composition and compatible structure of the major desialylated N-glycans from 
OVM cells.  
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Plasma Microsomal
Calculated membrane fraction
[M+Na]
+
HPAEC-PAD
fraction
1891.7 1891.5 m, n - - HexNAc6Hex3dHex
1905.6 1905.6* p, o - 1905.6 HexNAc2Hex9
1955.7 1955.7* k, m - - HexNAc4Hex5dHex2
2012.7 2012.5 n - - HexNAc5Hex5dHex
2028.7 2028.5 p, o 2028.7 2028.7 HexNAc5Hex6
2053.8 2053.5 n - - HexNAc6Hex4dHex
2174.8 2174.5 n, o, p 2174.7 2174.8 HexNAc5Hex6dHex
2215.8 2215.5 o, l - - HexNAc6Hex5dHex
2377.9 2377.8 o - - HexNAc6Hex6dHex
2393.8 2393.8* p - - HexNAc6Hex7
2539.9 2539.5 o, p 2539.9 2539.9 HexNAc6Hex7dHex
2743.0 2742.9* p - - HexNAc7Hex7dHex
2905.0 2904.7 p - - HexNAc7Hex8dHex
Vesicles
Proposed composition Compatible structure
m/z m/z m/z
Table II. Observed mass signals (m/z) by MALDI-TOF-MS analysis. Proposed 
composition and compatible structure of the major desialylated N-glycans from 
OVM cells (continued).  
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Plasma Microsomal
Calculated membrane fraction
[M+Na]
+
HPAEC-PAD
fraction
3270.2 3270.1* p - - HexNAc8Hex9dHex
Vesicles
Proposed composition Compatible structure
m/z m/z m/z
Table II. Observed mass signals (m/z) by MALDI-TOF-MS analysis. Proposed 
composition and compatible structure of the major desialylated N-glycans from 
OVM cells (continued).  
 
 
 
HexNAc, N-acetylhexosamine (GlcNAc/GalNAc); dHex, deoxyhexose (Fuc); Hex, 
hexose (Man or Gal). Asterisk denotes compound only detected in the MALDI-
TOF-MS analysis of the separated fractions from the HPAEC-PAD analysis (Figure 
23, C). Letters underlined represent the HPAEC-PAD fractions where m/z signal 
was predominantly observed. Only one or two possible glycan structures, 
compatible with the proposed compositions, are shown. Graphical representations 
of glycans are consistent with the nomenclature of the Consortium for Functional 
Glycomics. 
 
 
4.5. Discussion 
 
 Vesicles secreted by cells, including exosomes, are released by 
ovarian tumour cells (Gutwein et al., 2005) and are found in the blood and 
malignant ascites of the patients (Li et al., 2009; Runz et al., 2007). 
Furthermore, they are potential targets for the discovery of new disease 
biomarkers.  
 Alterations in glycosylation constitutes a common trait in many types 
of cancer, and antibodies against glycan epitopes at the cell surface have 
been used as diagnostic for several carcinomas (Peracaula et al., 2008). 
Lectin profiling studies previously performed in our group showed that 
exosomes secreted from ovarian tumour SKOV3 cells were enriched in 
specific mannose and sialic acid-containing glycoproteins (Chapter 3). In 
the present study we have shown by lectin blot that the glycosylation profile 
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of SKOV3-secreted vesicles was also different from other membrane 
enriched fractions, namely plasma membrane and microsomal enriched 
fractions. Our observations are in agreement with the results obtained 
using lectin microarrays in T-cells microvesicles that showed enrichment in 
high mannose and sialic acid-containing structures, as well as complex N-
glycans, and fucosylated structures in comparison with cell membranes 
micellae (Krishnamoorthy et al., 2009). Furthermore, the results allowed the 
identification of glycoproteins that are specific for secreted vesicles and 
possibly constitute exosomes markers. Further studies are required to 
purify and characterize those proteins by lectin affinity chromatography, 
followed by peptide mass fingerprinting. Antibodies raised against the 
polypeptide part will allow clarifying if specific proteins or protein glycoform 
are enriched in exosomes. 
 In addition, lectin detection revealed that SKOV3- and OVM- 
secreted vesicles had specific α2,3- and/or α2,6-linked NeuAc-containing 
glycoproteins that were not detected in other fractions. Since altered 
expression of certain sialic acid types or their linkages can have prognostic 
significance in several human cancers (reviewed in Li et al., 2010) it will be 
interesting to analyse the profile of native oligosaccharides from secreted 
vesicles and from the other membrane enriched fractions.  
 In order to further elucidate the N-glycan structures in the secreted 
vesicles from ovarian tumour cells, relatively to plasma membrane and 
microsomal fractions, SKOV3 and OVM cells were analysed by HPAEC-
PAD followed by MALDI-TOF-MS. As a common feature the results 
indicated the presence of glycans of the di-, tri- and tetraantennary type 
with proximal Fuc in secreted vesicles of SKOV3 and OVM cells, as well as 
in plasma membrane and microsomal fractions. The abundance of 
proximally fucosylated complex partially agalactosylated glycan structures 
in all fractions of SKOV3 cells was also detected.  
N-glycosylation of secreted vesicles 
 
117 
 A higher amount of high mannose structures was found in 
microsomal fractions of both SKOV3 and OVM cell lines. Since the 
endoplasmic reticulum is a major component of the microsomal fraction 
(Michelsen and Hagen, 2009) these high mannose glycans probably 
correspond to unprocessed structures characteristic of glycoproteins in 
transit or resident in the endoplasmic reticulum. 
 Moreover, the results suggested the presence of the LacdiNAc motif 
in SKOV3-secreted vesicles, which was in agreement with the WFA 
detection of specific bands in secreted vesicles. Partially agalactosylated 
glycans and the LacdiNAc motif have already been described in 
endogenous cellular and supernatant glycoproteins from SKOV3 cells 
(Machado et al., 2011). The LacdiNAc motif is associated with 
glycoproteins secreted by tumour cells such as ribonuclease I found in 
pancreatic tumour cells (Peracaula et al., 2003), plasminogen activator 
from Bowes melanoma cells (Chan et al., 1991), and glycodelin-A that is 
increased in many gynecological tumours (Horowitz et al., 2001).  
  Glycan profiles of secreted vesicles from the two cell lines studied 
were more heterogeneous than the plasma membrane or the microsomal 
fraction. The results also suggested a comparatively higher amount of more 
processed glycans of the tri- and tetraantennary types in secreted vesicles 
in comparison with plasma membrane and microsomal fractions for the 
OVM cells. This effect could be due to more processed glycoforms of a 
certain glycoprotein being enriched in exosomes, as suggested for 
ADAM10 (Chapter 2). Alternatively, the enrichment of specific glycoproteins 
with more processed glycans in exosomes would be plausible. To explore 
these hypothesis further work is required in characterizing purer exosome 
fractions, in exploring additional cell lines, and in improving glycan 
separation, possibly after labelling, for quantitation. 
 From our knowledge this is the first study endeavouring the detailed 
structural analysis of the N-glycans present in glycoproteins from ovarian 
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tumour-secreted vesicles.  In this work, secreted vesicles were isolated by 
ultracentrifugation at 100,000 x g since this fraction has been shown to be 
enriched in exosomes (Théry et al., 2006). Preliminary results using 
Nanoparticle Tracking Analysis (Nanosight) revealed that the majority of the 
isolated SKOV3- and OVM-secreted vesicles had average sizes of 134 and 
113 nm, respectively. Nonetheless, vesicles with smaller and larger 
dimensions were also detected (data not shown). Secreted vesicles can be 
further purified using a sucrose gradient. Purified exosomes have a density 
of 1.13-1.19 g/ml and have a size between 40-100 nm (Simons and 
Raposo, 2009). Therefore, it would be interesting to analyse the N-glycans 
from purified exosomes not only to confirm if N-glycan structures enriched 
in the secreted vesicles are found in exosomes but also to investigate if 
additional specific structures are found. 
 The knowledge of N-glycan structures present in purified exosomes 
could provide the basis for further studies on the mechanisms involved in 
exosomes biogenesis. In a more applied perspective, the identification of 
specific N-glycans might give new insights for biomarkers discovery and 
cancer vaccination. 
 
 
4.6. Acknowledgements 
 
 We thank Sebastian Kandzia and Dr. Harald S. Conradt, 
GlycoThera, Germany, for HPAEC-PAD and MALDI-TOF-MS analysis. 
 This work was funded by projects PIC/IC/82765/2007 and 
PTDC/SAU-NEU/100724/2008, Fundação para a Ciência e a Tecnologia, 
Portugal. CE had a Ph.D. fellowship from Fundação para a Ciência e a 
Tecnologia. 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
 
 
 
 
General discussion and conclusions 
 
 
 
Chapter 5 
120 
General discussion and conclusions 
 
121 
5. General discussion and conclusions 
 
 
5.1. General discussion and perspectives 
 
Ovarian cancer has the highest mortality rate among the 
gynecological malignancies in the Western world. Long-term survival has 
not changed significantly in the last two decades, largely due to inadequate 
diagnostic approaches and the lack of efficient treatments.  
Aberrant protein glycosylation is an early event of oncogenic 
transformation; therefore, glycan structures represent ideal targets for 
tumour specific diagnosis and new anti-tumour therapeutic strategies. In 
ovarian cancer a number of proteins were found to be aberrantly 
glycosylated, including CA125 (Jankovic and Milutinovic, 2008), alpha-1-
proteinase inhibitor, haptoglobin (Turner et al., 1995), immunoglobulin G, 
and other acute phase proteins (Saldova et al., 2007). Moreover, an 
increased sialylation of proteins and deregulated sialylation pathways were 
also observed (Aranganathan et al., 2005).  
Exosomes are small membrane vesicles that are secreted by 
several cell types, including ovarian tumour cells (Gutwein et al., 2005), and 
have been found in vivo in several biological fluids, such as blood and 
malignant ascites of ovarian cancer patients (Caby et al., 2005; Runz et al., 
2007). Exosomes have the ability to interact with other cells and were 
shown to contribute to tumour progression by promoting immune escape 
mechanisms, facilitating extracellular matrix degradation and transferring 
proteins and genetic material among cells (reviewed in Muralidharan-Chari 
et al., 2010).  
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Although many studies have been carried out to identify the protein, 
lipid and RNA composition of exosomes, little is known about the 
glycosylation profile of these secreted vesicles and the potential role of N-
glycans in protein sorting to exosomes or in recognition and uptake of 
exosomes by target cells. 
In this context, the intent of this Thesis was to investigate the protein 
glycosylation profile of vesicles secreted from ovarian tumour cells. In 
addition, the biological role of N-glycans in ADAM10 protein sorting to 
exosomes and in the internalization of SKOV3 exosomes by SKOV3 cells 
was explored.  
 
5.1.1. Exosome specific glycoproteins/glycoforms 
 
Proteomic studies have shown that glycoproteins, similarly to other 
proteins, are found in exosomes (Simpson et al., 2008). In addition, some 
reports have described the presence of heavily glycosylated forms of some 
proteins, such as FAS-L (Abrahams et al., 2003) and the prion precursor 
protein (Vella et al., 2007), in secreted vesicles that are not detected in 
cellular extracts. In this context, here the use of lectins with different 
carbohydrate specificities revealed that vesicles secreted from SKOV3 and 
OVM cells contained specific glycoproteins, in particular proteins containing 
α2,3-linked sialic acid, that were not detected in cellular extracts, plasma 
membrane or microsomal enriched fractions (Chapter 4). Vesicles secreted 
from SKOV3 cells were also found to strongly bind Con A, which 
recognizes predominantly high mannose glycans, compared with other 
fractions (Chapter 3 and Chapter 4). Furthermore, secreted vesicles from 
the two cell lines were found to contain a higher amount of N-glycans than 
plasma membrane or microsomal fractions, as shown by the peak 
intensities in the HPAEC-PAD profiles (Chapter 4). These results together 
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showed that specific glycoproteins and/or glycoforms were enriched in 
ovarian tumour secreted vesicles. The molecular mechanisms underlying 
this enrichment are still not known. 
To date, several mechanisms of protein sorting to exosomes have 
been proposed. The most studied involves the recognition of ubiquitinated 
proteins by the ESCRT machinery (reviewed in Lakkaraju and Rodriguez-
Boulan, 2008; Simons and Raposo, 2009). In SKOV3 cells, this pathway 
might account for the recruitment of some proteins to exosomes since 
exosomal proteins were found to be heavily ubiquitinated in comparison 
with cellular proteins (Chapter 2) and SKOV3 exosomes contained 
TSG101, a protein that is involved in the ESCRT sorting machinery 
(unpublished data). Overexpressed ADAM10-HA was also found to be 
ubiquitinated in exosomes, however due to the low protein expression it 
was not possible to determine if endogenous ADAM10 was also 
ubiquitinated in exosomes (Chapter 2). To substantiate the possibility of 
glycoproteins being sorted to exosomes via ESCRT, RNA interference 
targeting different mRNAs coding for proteins involved in the ESCRT 
machinery could be used and the presence of different glycoproteins 
monitored in exosomes. 
Nevertheless, not all proteins found in exosomes are ubiquitinated 
and other sorting mechanisms might coexist in the same cells, depending 
on the cargo protein or even for the same protein. Mechanisms involving 
partitioning into cholesterol and sphingolipid-rich lipid microdomains (lipid-
rafts and tetraspanin webs) and higher-order oligomerization (aggregation 
of oligomers) at the plasma membrane might be involved in protein sorting 
to exosomes (de Gassart et al., 2003; Trajkovic et al., 2008; Lakkaraju et 
al., 2008; Schorey et al., 2008). On the other hand, N-glycans have been 
implicated in protein sorting mechanisms, for example, acting as apical 
targeting signals for secretory proteins in epithelial cells (Scheiffele et al., 
1995). Moreover, they might interact with galectins at the cell surface 
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leading to their enrichment in membrane lipid domains (Garner and Baum, 
2008) and have been described to mediate oligomerization via interaction 
with lectins (Vidal et al., 1997). Therefore, it is possible that glycans could 
also play a role on protein sorting to exosomes and consequently the 
presence of specific glycoproteins and/or glycoforms in secreted vesicles 
could be the result of more complex type glycoforms being preferentially 
sorted to the multivesicular bodies and/or to the exosomes. A glycan-
dependent protein sorting mechanism that targets proteins to microdomains 
from where both microvesicles and HIV particles emerge has already been 
proposed in T-cells (Krishnamoorthy et al., 2009). Further studies are still 
required to understand if glycosylated proteins have specific mechanisms 
of sorting to exosomes and if glycans play any role in this sorting process. It 
is also feasible that different protein glycoforms are sorted to exosomes 
through different mechanisms. 
The enrichment of specific N-glycans in exosomes could also result 
from the fact that more processed glycoforms are less susceptible to 
proteolysis. Thus N-glycans could have a role in the protection of proteins 
present in secreted vesicles.  The role of N-glycans in protein stability and 
steric protection of susceptible sites from attack by proteases is well known 
(Varki, 1993; Opdenakker et al., 1993). This protection by N-glycans has 
been observed for several proteins, including ADAM10, where the removal 
of N439 glycosylation site exposed a particular region susceptible to 
protease degradation (Chapter 2). Supporting the hypothesis that 
exosomes are enriched in proteolytic activity are the observations that 
active metalloproteases, such as the membrane type 1 matrix 
metalloproteinase (Hakulinen et al., 2008) and ADAM10 (Stoeck et al., 
2006), are present in exosomes and are capable of cleaving protein 
substrates. Accordingly, in SKOV3 exosomes, an ADAM10 proteolytic 
product resulting from metalloprotease cleavage was found in exosomes 
and not in cellular extracts (Chapter 2).  
General discussion and conclusions 
 
125 
More studies are still necessary to fully elucidate the mechanisms 
underlying the enrichment of specific glycoproteins/glycoforms in 
exosomes.  
 
5.1.2. Internalization of exosomes by target cells  
 
Exosomes can interact and be internalized by target cells. They can 
deliver cytokines, growth factors, receptors and genetic material, thus 
conferring new functional properties to the recipient cells. The process of 
internalization can occur through direct fusion of the exosomes with the 
plasma membrane or alternatively, exosomes can enter the cells via 
clathrin-mediated endocytosis, phagocytosis or macropinocitosys (Morelli, 
et al., 2004; Feng et al., 2010; Fitzner et al., 2011). In Chapter 3, SKOV3 
cell-derived exosomes were found to be internalized by SKOV3 cells in an 
energy-dependent process, via various endocytic pathways. Incubation with 
different endocytic inhibitors showed that a clathrin-mediated endocytosis 
pathway, macropinocytosis and a cholesterol associated pathway 
independent of caveolae were associated with the uptake. 
The initial recognition events that precede uptake may involve 
several molecules such as proteins (Chapter 3) (Simons and Raposo, 
2009), lipids (Keller et al., 2009) or glycans (Hao et al., 2007) present at the 
cell surface or in the exosomes membrane. Glycans have been shown to 
bind specifically carbohydrate receptors (lectins) on other cell surfaces and 
mediate several biological interactions such as cell-cell adhesion and host-
pathogen recognition (reviewed in Brooks, 2009). Many pathogens, such as 
HIV and the influenza virus, are dependent on the recognition of specific 
glycan epitopes for the process of infection to occur. Since virus and 
exosomes might share similar biogenesis and internalization pathways 
(Izquierdo-Useros et al., 2011), it is plausible that glycans could also have a 
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role in exosomes uptake by target cells. Accordingly, studies have shown 
that in dendritic cells exosome uptake was at least in part mediated by a C-
type lectin and was specifically inhibited by mannose and N-
acetylglucosamine (Hao et al., 2007). In macrophages, lactose was found 
to reduce exosomes uptake probably through its action on galectin-5 
(Barres et al., 2010).  
In SKOV3 cells, NeuAc removal from exosomes caused a trend 
towards an increase of uptake but sugar inhibition assays with fucose, 
mannose, galactose, N-acetylglucosamine or lactose reduced exosomes 
uptake to the same extent as the control glucose (Chapter 3). Overall these 
results suggested that N-glycans did not play a major role in exosomes 
uptake by ovarian tumour SKOV3 cells. 
The observation that N-glycans are important for exosomes uptake 
in antigen presenting cells such as dendritic cells or macrophages but not 
in tumour cells, like SKOV3 cells, might be explained by the fact that 
different cell types have different internalization mechanisms depending on 
their function. Antigen presenting cells were shown to recognize pathogens 
through specific carbohydrate-binding proteins, especially C-type lectins, 
galectins and sialic acid-specific lectins of the Siglec family that recognize 
specific glycan structures such as Lewisx, Lewisy , GlcNAc, high mannose 
structures and sialic acid (reviewed in van Kooyk and Rabinovich, 2008; 
Davicino et al., 2011). This interaction leads to antigen presentation and 
signalling in antigen presenting cells, thus modulating immune responses. 
Similarly dendritic cells were shown to internalize exosomes that can also 
mediate immune responses either as activators or as inhibitors depending 
on their source (Théry et al., 2009). It would be interesting to investigate the 
role of N-glycans in the uptake of SKOV3 cell-derived exosomes by 
dendritic cells and explore the potential differences between the 
internalization mechanisms of antigen-presenting and tumour cells. 
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The interaction and internalization of tumour cell-derived exosomes 
by the same tumour cells that produced them raises several questions, 
namely the in vivo role of this phenomenon. Microvesicles secreted from 
tumour cells can be internalized by normal cells and transfer RNA and 
proteins that promote tumour growth (Skog et al., 2008). Similarly, tumour 
cell-derived exosomes could also be internalized by the same tumour cells 
to transfer information and facilitate tumour progression and dissemination. 
For example, glioblastoma secreted vesicles were shown to transfer the 
oncogenic form of the epidermal growth factor receptor, known as 
EGFRvIII, between cells with an aggressive phenotype and glioblastoma 
cells lacking EGFRvIII (Al-Nedawi et al., 2008) and exosomes from 
melanoma cells were found to transfer the tumour-associated protein 
caveolin-1 to melanoma cells that do not express this protein (Parolini et 
al., 2009). Further investigation is required to clarify all the biological roles 
of tumour exosomes uptake by the same cells that produce them. This 
knowledge could help to unveil the role of secreted vesicles in tumour 
progression and dissemination. 
 
 
5.1.3. Exosomes from ovarian tumour cells as biomarkers and 
potential therapeutic targets   
 
A major goal in the field of ovarian cancer research is to identify 
biomarkers for the early diagnosis of the disease. The ability to isolate 
exosomes, in a non-invasive manner, from different physiological sources 
such as blood, holds significant potential. Several studies have shown that 
microRNA profile and proteins expressed in exosomes might be used as 
markers for the early detection and diagnosis of diseases, for determining 
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prognosis, and for prediction of therapeutic efficacy (Taylor and Gercel-
Taylor, 2008; Rabinowits et al., 2009; Li et al., 2009; Lu et al., 2009). 
Cell surface glycosylation is one of the major changes that occur in 
cancer cells. Alterations include the synthesis of highly branched and 
heavily sialylated glycans, the premature termination of biosynthesis 
resulting in the expression of uncompleted forms and the re-expression of 
glycosidic antigens of fetal type (reviewed in Dall'Olio, 1996). As a result, 
many of the markers used to detect tumours are glycoproteins and glycan 
epitopes (Peracaula et al., 2008). 
In this study, the analysis of different human ovarian tumour cell 
lines and neuroglioma H4 cells revealed that secreted vesicles contained 
specific glycoproteins, in particular high mannose and sialic acid-containing 
proteins, which were not found in cellular extracts or other membrane 
enriched fractions such as plasma membrane or microsomal fractions 
(Chapter 3 and Chapter 4). In the future, the purification of these specific 
glycoproteins, by lectin affinity chromatography, and their characterization 
might help to establish if they constitute exosome markers. Additionally, 
antibodies raised against these glycoproteins could be used to screen for 
the presence of exosome markers in other cell lines. 
Studies are still required to determine if the glycoproteins, detected 
by lectin blot in secreted vesicles, are specific or enriched in tumour cell-
derived vesicles. If confirmed, their use as cancer markers could be 
explored. Furthermore, given that the rate of exosomes release has been 
shown to correlate with tumour invasiveness (Ginestra et al., 1999), it 
would be interesting to explore the possibility of using these glycoproteins 
to monitor disease progression.  
The structural analysis of the glycan epitopes of ovarian tumour 
cells by HPAEC-PAD and MALDI-TOF-MS (Chapter 4) suggested the 
presence of the LacdiNAc motif in SKOV3 cells secreted vesicles (Chapter 
4). The LacdiNAc motif has already been described in endogenous cellular 
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and secreted glycoproteins from SKOV3 cells (Machado et al., 2010) and it 
has previously been reported in glycoproteins associated to tumour cells, 
such as, ribonuclease I found in pancreatic tumour cells (Peracaula et al., 
2003), plasminogen activator from Bowes melanoma cells (Chan et al., 
1991) and glycodelin-A that is increased in many gynecological tumours 
(Horowitz et al., 2001). Since exosomes can be collected from biological 
fluids, the presence of the LacdiNac motif could be investigated in 
exosomes from the blood or ascitic fluid of ovarian cancer patients to 
determine the potential use of this motif as a diagnosis and/or prognosis 
marker. 
The use of exosomes in immunotherapy has also become a 
promising area of research. Exosomes are good candidates for the 
selective delivery of drugs, small molecules or agents for gene therapy 
mainly due to their ability to evade immune recognition, cell-specificity, 
efficient cargo delivery and low immunogenicity (reviewed in Tan et al., 
2010). Using nanotechnology, exosomes can also be engineered to carry 
cytokines, DNA, RNA, adjuvants, labels, costimulatory signals, and gene 
therapy vectors (reviewed in Tan et al., 2010). 
Several studies have already shown the potential of exosomes to 
carry and transfer information. Exosomes derived from murine mast cells 
were found to deliver functional mRNAs to human mast cells (Valadi et al., 
2007) and the delivery of curcumin by exosomes was found to be more 
effective in preventing septic shock than the delivery using liposomes (Sun 
et al., 2010). Recently, purified exosomes, loaded with exogenous siRNA 
and targeted to neurons, were shown to deliver siRNA specifically to mouse 
brain, suggesting that exosomes might cross the blood-brain barrier 
(Alvarez-Erviti et al., 2011). 
The observation that B-cell derived exosomes could bear functional 
MHC class II complexes leading to antigen specific T-cell activation in vitro 
(Raposo et al., 1996) and the capacity of exosomes released from dendritic 
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cells, pulsed with tumor antigens, to stimulate T-cells and to promote anti-
tumour immune responses in vivo (Zitvogel et al., 1998) has lead to clinical 
studies exploiting the application of exosomes as therapeutic vaccines.  To 
date, three Phase I clinical trials have been conducted involving the 
application of dendritic cell derived exosomes to elicit immune responses 
against established tumours of colorectal, melanoma and non-small cell 
lung carcinoma (Dai et al., 2008; Escudier et al., 2005; Morse et al., 2005).  
In all studies, exosomes were proven to be safely administered but the 
immune responses were very limited. In the future immune responses will 
need to be enhanced by using proper adjuvants or by engineering 
exosomes with tumour antigens to make them more recognizable to the 
immune system (Tan et al., 2010). A Phase II clinical trial using dendritic 
cell-derived exosomes, with enhanced bioactivity, in inoperable non small 
cell lung cancer is currently in progress (ClinicalTrials.gov identifier: 
NCT01159288).  
The identification of glycoproteins and/or glycans enriched in 
vesicles secreted by tumour cells may provide with specific and more 
efficient targets for the development of future cancer vaccines. Several 
carbohydrate-based vaccines have already been developed and some 
have proceeded into clinical trials (reviewed in Vliegenthart, 2006; 
Astronomo and Burton, 2010). As an example, the LacdiNAc motif that is 
uncommon in mammals but that is frequently expressed by helminth 
parasites was found to induce an immune response mediated by galectin-3 
(van den Berg et al., 2004). Since the LacdiNAc is found in SKOV3 
secreted vesicles, the use of this motif in the development of a vaccine 
against ovarian cancer could be explored. 
In a different approach, exosomes immune properties could be 
influenced by changing their glycoprotein and/or glycan composition. 
Exosomes could be modified to carry or overexpress specific glycoproteins 
or glycan epitopes in order to increase their immunogenicity and enhance 
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possible immune responses against the tumour from where they originated. 
This could be achieved with the genetic engineering of the corresponding 
cell lines (overexpression of the target glycoprotein and/or engineering of 
the glycosylation pathway) or with the modulation of exosome glycosylation 
using glycosyltransferases in vitro. Additional studies are required to 
understand the potential of the glycoproteins and glycans, identified in 
secreted vesicles, in the induction of immune responses against tumour 
cells. 
The study performed in this Thesis used vesicles secreted from 
ovarian tumour cells in culture; however, this approach has some obvious 
limitations. Cells in culture have been selected through successive 
passages and their exosomes may display a molecular composition distinct 
from patient exosomes. Moreover, most human tumours are a 
heterogeneous mixture of different cells that potentially release exosomes 
as well as other vesicles. It would be interesting to perform a detailed N-
glycosylation analysis of exosomes derived from blood and malignant 
ascites of patients with ovarian carcinoma to confirm and possibly identify 
new glycoproteins and/or N-glycans that could be used as biomarkers 
and/or therapeutic targets in ovarian cancer. 
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5.2. General conclusions 
 
The work described in this Thesis allowed a better understanding of 
the protein glycosylation of vesicles secreted by ovarian tumour cells. 
N-glycosylation was shown to have important functions in ADAM10 
processing, protection from proteolysis, and full-enzyme activity. 
Exosomes from SKOV3 ovarian tumour cells were shown to be 
internalized by the same cell line that produced them via several endocytic 
pathways but N-glycans had no major role in the internalization process.   
SKOV3 secreted vesicles were found to be enriched in specific 
mannose- and sialic acid-containing glycoproteins that were not present in 
cellular extracts, plasma membrane or microsomal fractions.   
The N-glycan profiles of cellular fractions and vesicles of SKOV3 
and OVM cells showed some distinguishing features: the microsomal 
fractions were abundant in high mannose glycans; the profiles of secreted 
vesicles were more heterogeneous than those of plasma membrane or 
microsomal fractions and contained complex type glycans, which for 
SKOV3 cells were partially truncated; the LacdiNAc motif was found 
enriched in SKOV3 vesicles. 
In summary, this work contributed to a better knowledge of the 
protein glycosylation of vesicles secreted by tumour cells and opens new 
perspectives in the use of specific glycoproteins and/or N-glycans as 
potential biomarkers and therapeutic targets. 
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Supplementary Figure 1 (continued) 
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Supplementary Figure 1 (continued) 
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Supplementary Figure 2  
 
 
 
 
 
 
Supplementary material 
 
139 
Supplementary Figure 2 (continued) 
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Supplementary Figure 1. MALDI/TOF-MS analysis of desialylated N-
linked oligosaccharides from SKOV3 secreted vesicles, obtained from 
fractions a-j (Figure 22).   
 
 
 
Supplementary Figure 2. MALDI/TOF-MS analysis of desialylated N-
linked oligosaccharides from OVM secreted vesicles, obtained from 
fractions k-p (Figure 23).   
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